

**ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications**

**IND Number:** 155481

**Principal Investigator:** Adrian Hernandez, MD, MHS  
Duke Clinical Research Institute  
[REDACTED]

**Co-Principal Investigator/IND Sponsor:** Susanna Naggie, MD, MHS  
Duke Clinical Research Institute  
[REDACTED]

**Data Coordinating Center Investigator:** Chris Lindsell, PhD  
Duke Clinical Research Institute  
[REDACTED]

**Lead Funding Agency:** National Center for Advancing Translational Sciences

**Version:** 12.0

**Date:** 05JUN2024

**NCT ID:** NCT06042855

**Statement of Compliance**

This trial will be conducted in compliance with the International Council for Harmonisation (ICH) E6 (R2) guideline for Good Clinical Practice (GCP), and the applicable regulatory requirements from the United States (US) Code of Federal Regulations (CFR), including 45 CFR 46 (Human Subjects Protection); 21 CFR 312 (Investigational New Drug); 21 CFR 50 (Informed Consent), and 21 CFR 56 (Institutional Review Board).

All individuals who are responsible for the conduct, management, or oversight of this study have completed Human Subjects Protection and ICH GCP Training.

**Site Principal Investigator Statement**

I have read the protocol, including all appendices, and the package insert(s)/product label(s), and I agree that the protocol contains all necessary details for my staff and me to conduct this study as described. I will personally oversee the conduct of this study as outlined herein and will make a reasonable effort to complete the study within the time designated. I agree to make all reasonable efforts to adhere to the attached protocol.

I will provide all study personnel under my supervision with copies of the protocol and access to all information provided by the sponsor or the sponsor's representative. I will discuss this material with study personnel to ensure that they are fully informed about the efficacy and safety parameters and the conduct of the study in general. I am aware that, before beginning this study, the IRB, or equivalent oversight entity must approve this protocol in the clinical facility where it will be conducted.

I agree to obtain informed consent from participants, as required by the IRB of record and according to government regulations and ICH guidelines. I further agree to report to the sponsor or its representative any adverse events in accordance with the terms of this protocol and the US CFR, Title 21, part 312.64, ICH GCP 4.11. I further agree to ensure the study is conducted in accordance with the provisions as stated and will comply with the prevailing local laws and customs.

---

Site Principal Investigator Name (Print)

---

Site Principal Investigator Signature

---

Date

## Table of Contents

<b>1.</b>	<b>Protocol Summary .....</b>	<b>13</b>
1.1.	Synopsis .....	13
1.2.	Schema.....	20
<b>2.</b>	<b>Introduction.....</b>	<b>22</b>
2.1.	Study Rationale.....	22
2.2.	Background.....	22
2.3.	Benefit/Risk Assessment .....	23
2.3.1.	Risk Assessment .....	23
2.3.2.	Benefit Assessment.....	23
<b>3.</b>	<b>Objectives and Endpoints .....</b>	<b>24</b>
3.1.	Acute disease .....	24
3.2.	Post-acute disease (Appendix G).....	25
	<b>Study Design .....</b>	<b>27</b>
3.3.	Overall Design .....	27
3.4.	End of Study Definition.....	28
<b>4.</b>	<b>Study Population.....</b>	<b>29</b>
4.1.	Inclusion Criteria .....	29
4.2.	Exclusion Criteria .....	29
4.3.	Recruitment and Engagement.....	29
4.3.1.	Participant Recruitment .....	29
4.3.2.	Participant Engagement .....	29
4.3.3.	Participant Randomization Process.....	30
4.4.	Screen Failures.....	30
4.5.	Enrollment .....	31
<b>5.</b>	<b>Study Drug(s) .....</b>	<b>32</b>
5.1.	Repurposed Medication Treatments .....	32
5.2.	Placebo.....	32
5.3.	Study Drug Accountability .....	32
5.4.	Concomitant Therapy .....	32
5.5.	Intervention After the End of the Study.....	32
<b>6.</b>	<b>Participant Withdrawal/Termination and Study Termination.....</b>	<b>33</b>
6.1.	Participant Withdrawal/Termination .....	33
6.2.	Premature Termination or Suspension of the Study .....	33
6.3.	Lost to Follow-up.....	33
<b>7.</b>	<b>Study Assessments and Procedures.....</b>	<b>35</b>
7.1.	Schedule of Events.....	36
7.1.1.	Screening.....	37
7.1.2.	Intervention Period.....	37
7.1.3.	Follow-up Period .....	38
7.1.4.	Final Visit.....	39
7.2.	Clinical Assessments .....	39
7.3.	Quality of Life Questionnaires .....	41

<b>8.</b>	<b>Safety Assessments.....</b>	<b>42</b>
8.1.	Adverse Events and Serious Adverse Events .....	42
8.1.1.	Adverse Device Effect (ADE) and Unanticipated Adverse Device Effect (UADE).....	42
8.1.2.	Collection Period for AE and SAE Information .....	43
8.1.3.	Assessing Causality of a Serious Adverse Event.....	44
8.1.4.	Reporting and Monitoring of SAEs .....	44
8.1.5.	Events of Special Interest.....	45
8.2.	Unanticipated Problem (UP) and Terminations.....	46
8.2.1.	Definition of Unanticipated Problem.....	46
8.2.2.	Reporting of an Unanticipated Problem .....	46
<b>9.</b>	<b>Statistical Considerations.....</b>	<b>47</b>
9.1.	Statistical Hypotheses .....	47
9.1.1.	Primary Hypothesis.....	47
9.2.	Sample Size Determination .....	47
9.3.	Randomization.....	48
9.4.	Blinding .....	48
9.5.	Populations for Analyses .....	48
9.6.	Statistical Analyses .....	49
9.6.1.	General Considerations.....	49
9.6.2.	Statistical Modeling.....	49
9.6.3.	Assessing Effectiveness (Acute Disease Primary Objective).....	49
9.6.4.	Acute Disease Interim Analyses (IA), Early Stopping, and Type- I Error Control.....	50
9.6.5.	Sensitivity and Supplementary Analyses.....	52
9.6.6.	Differential Treatment Effects and Subgroup Analyses (Acute Disease).....	52
9.6.7.	Secondary Clinical Endpoint (Acute Disease).....	52
9.6.8.	Exploratory Analysis (Acute Disease).....	53
9.6.9.	Adherence and Retention Analysis.....	53
9.7.	Interim Reporting.....	53
9.8.	Independent Data Monitoring Committee (IDMC) .....	54
9.9.	Adjudication Committee.....	54
<b>10.</b>	<b>Ethical Standards.....</b>	<b>55</b>
10.1.	Institutional Review Board (IRB).....	55
10.2.	Informed Consent Process .....	55
10.3.	Participant and Data Confidentiality.....	55
10.4.	Site Management and Quality Assurance .....	56
10.5.	Site Monitoring.....	56
<b>11.</b>	<b>Data Handling and Record Keeping .....</b>	<b>58</b>
11.1.	Data Collection and Management Responsibilities.....	58
11.2.	Study Records Retention .....	58
11.3.	Protocol Deviations.....	58
11.4.	Publication and Data Sharing Policy .....	58

<b>12.</b>	<b>Study Leadership .....</b>	<b>60</b>
<b>13.</b>	<b>Summary of Changes.....</b>	<b>61</b>
<b>14.</b>	<b>References.....</b>	<b>69</b>
<b>15.</b>	<b>Appendix A (Enrollment Closed 04FEB2022) – Ivermectin 400 .....</b>	<b>76</b>
15.1.	Risk Assessment .....	76
15.2.	Additional Appendix-Level Exclusion Criteria.....	77
15.2.1.	Precautions.....	77
15.3.	Ivermectin Information.....	78
15.3.1.	Formulation, Appearance, Packaging, and Labeling .....	78
15.3.2.	Drug Dispensing, Storage, and Stability.....	78
15.3.3.	Dosing and Administration.....	78
15.3.4.	Rationale for Selection of Dose .....	78
15.4.	Placebo Information.....	80
15.4.1.	Formulation, Appearance, Packaging, and Labeling .....	80
15.4.2.	Drug Dispensing, Storage, and Stability.....	80
15.4.3.	Dosing and Administration.....	80
15.5.	Events of Special Interest .....	80
<b>16.</b>	<b>Appendix B (Enrollment Closed 27MAY2022) – Fluvoxamine Maleate .....</b>	<b>81</b>
16.1.	Risk Assessment .....	81
16.2.	Additional Appendix-Level Exclusion Criteria.....	82
16.2.1.	Precautions.....	83
16.3.	Fluvoxamine Information .....	83
16.3.1.	Formulation, Appearance, Packaging, and Labeling .....	83
16.3.2.	Drug Dispensing, Storage, and Stability.....	84
16.3.3.	Dosing and Administration.....	84
16.3.4.	Rationale for Selection of Dose .....	84
16.4.	Placebo Information.....	87
16.4.1.	Formulation, Appearance, Packaging, and Labeling .....	87
16.4.2.	Drug Dispensing, Storage, and Stability.....	87
16.4.3.	Dosing and Administration.....	87
16.5.	Events of Special Interest .....	87
<b>17.</b>	<b>Appendix C (Enrollment Closed 08FEB2022) – Fluticasone Furoate.....</b>	<b>88</b>
17.1.	Risk Assessment .....	88
17.2.	Additional Appendix-Level Exclusion Criteria.....	89
17.2.1.	Precautions.....	89
17.3.	Fluticasone Furoate Information.....	89
17.3.1.	Formulation, Appearance, Packaging, and Labeling .....	90
17.3.2.	Drug Dispensing, Storage, and Stability.....	90
17.3.3.	Dosing and Administration.....	90
17.3.4.	Rationale for Selection of Dose .....	90
17.4.	Placebo Information.....	91

17.4.1.	Formulation, Appearance, Packaging, and Labeling .....	91
17.4.2.	Drug Dispensing, Storage, and Stability .....	91
17.4.3.	Dosing and Administration .....	92
17.5.	Events of Special Interest .....	92
17.6.	Safety Reporting for Fluticasone Furoate .....	92
<b>18.</b>	<b>Appendix D (Enrollment Closed 22JUL2022) – Ivermectin</b>	
	<b>600 .....</b>	<b>93</b>
18.1.	Risk Assessment .....	93
18.2.	Additional Appendix-Level Exclusion Criteria .....	93
18.2.1.	Precautions .....	93
18.3.	Ivermectin Information .....	93
18.3.1.	Formulation, Appearance, Packaging, and Labeling .....	93
18.3.2.	Drug Dispensing, Storage, and Stability .....	93
18.3.3.	Dosing and Administration .....	93
18.3.4.	Rationale for Selection of Dose .....	94
18.4.	Placebo Information .....	94
18.4.1.	Formulation, Appearance, Packaging, and Labeling .....	94
18.4.2.	Drug Dispensing, Storage, and Stability .....	94
18.4.3.	Dosing and Administration .....	94
18.5.	Events of Special Interest .....	94
<b>19.</b>	<b>Appendix E (Enrollment Closed 20JAN2023) – Fluvoxamine</b>	
	<b>Maleate 100 .....</b>	<b>95</b>
19.1.	Risk Assessment .....	95
19.2.	Additional Appendix-Level Exclusion Criteria .....	95
19.2.1.	Precautions .....	95
19.3.	Fluvoxamine Information .....	95
19.3.1.	Formulation, Appearance, Packaging, and Labeling .....	95
19.3.2.	Drug Dispensing, Storage, and Stability .....	95
19.3.3.	Dosing and Administration .....	95
19.3.4.	Rationale for Selection of Dose .....	95
19.4.	Placebo Information .....	96
19.4.1.	Formulation, Appearance, Packaging, and Labeling .....	96
19.4.2.	Drug Dispensing, Storage, and Stability .....	96
19.4.3.	Dosing and Administration .....	96
19.5.	Events of Special Interest .....	97
<b>20.</b>	<b>Appendix F (Enrollment Closed 23JUN2023) – Montelukast .....</b>	<b>98</b>
20.1.	Risk Assessment .....	98
20.2.	Additional Appendix-Level Exclusion Criteria .....	99
20.2.1.	Precautions .....	99
20.3.	Study Drug Information .....	99
20.3.1.	Formulation, Appearance, Packaging, and Labeling .....	99
20.3.2.	Drug Dispensing, Storage, and Stability .....	99
20.3.3.	Dosing and Administration .....	99
20.3.4.	Rationale for Selection of Dose .....	99
20.4.	Placebo Information .....	102

20.4.1.	Formulation, Appearance, Packaging, and Labeling .....	102
20.4.2.	Drug Dispensing, Storage, and Stability .....	102
20.4.3.	Dosing and Administration .....	102
20.5.	Events of Special Interest .....	102
<b>21.</b>	<b>Appendix G – Metformin Hydrochloride Immediate-Release .....</b>	<b>103</b>
21.1.	Risk Assessment .....	103
21.2.	Additional Appendix-Level Exclusion Criteria .....	103
21.2.1.	Precautions .....	104
21.3.	Study Drug Information .....	104
21.3.1.	Formulation, Appearance, Packaging, and Labeling .....	104
21.3.2.	Drug Dispensing, Storage, and Stability .....	104
21.3.3.	Dosing and Administration .....	104
21.3.4.	Rationale for Selection of Dose .....	105
21.4.	Placebo Information .....	107
21.4.1.	Formulation, Appearance, Packaging, and Labeling .....	107
21.4.2.	Drug Dispensing, Storage, and Stability .....	107
21.4.3.	Dosing and Administration .....	107
21.5.	Events of Special Interest .....	108
21.6.	Statistical Considerations for Acute Disease .....	108
21.7.	Statistical Considerations for Post-acute Disease .....	108
21.7.1.	Primary Hypothesis .....	108
21.7.2.	Sample Size Considerations .....	108
21.7.3.	Interim Analysis .....	109



**Abbreviations**

ACE	Angiotensin-converting Enzyme
ADE	Adverse Device Effect
AE	Adverse Event
ARB	Angiotensin II Receptor Blockers
ARNI	Angiotensin Receptor Neprilysin Inhibitor
BiPAP	Bilevel Positive Airway Pressure
BMD	Bone Mineral Density
BMI	Body Mass Index
CCC	Clinical Coordinating Center
CEA	Clinical Event Ascertainment
CFR	Code of Federal Regulations
CNS	Central Nervous System
CONSORT	Consolidated Standards of Reporting Trials
COPD	Chronic Obstructive Pulmonary Disease
cOR	Common Odds Ratio
COVID-19	Coronavirus Disease 2019
CPAP	Continuous Positive Airway Pressure
C-SSRS	Columbia-Suicide Severity Rating Scale
DCC	Data Coordinating Center
DIC	Disseminated Intravascular Coagulation
DR	Delayed-Release
DUA	Data Use Agreement
ECMO	Extracorporeal Membrane Oxygenation
EDC	Electronic Data Capture
ESI	Event of Special Interest
FDA	Food and Drug Administration
GCP	Good Clinical Practice
HbA1c	Hemoglobin A1c
HIPAA	Health Insurance Portability and Accountability Act
HIV	Human Immunodeficiency Virus
HR	Hazard Ratio
IA	Interim Analysis
IC <sub>50</sub>	Half-Maximal Inhibitory Concentration
ICF	Informed Consent Form
ICH	International Council for Harmonisation
ICMJE	International Committee of Medical Journal Editors
ICS	Inhaled Corticosteroid
ICU	Intensive Care Unit
IDMC	Independent Data Monitoring Committee
IDS	Investigational Drug Service
IR	Immediate-Release
IRB	Institutional Review Board
KO	Knockout
LPS	Lipopolysaccharide
MAOI	Monoamine Oxidase Inhibitors

mITT	Modified Intention to Treat
MOP	Manual of Procedures
NCATS	National Center for Advancing Translational Sciences
NIH	National Institute of Health
OCD	Obsessive Compulsive Disorder
OHRP	Office for Human Research Protections
OR	Odds Ratio
PASC	Post-Acute Sequelae of SARS-CoV-2 Infection
PCORI	Patient-Centered Outcomes Research Institute
PCR	Polymerase Chain Reaction
PHI	Personal Health Information
PHQ	Patient Health Questionnaire
PI	Principal Investigator
PPOS	Predicted Probability of Success
PROMIS	Patient-reported Outcomes Measurement Information System
QOL	Quality of Life
RNA	Ribonucleic Acid
RRT	Renal Replacement Therapy
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SARS-CoV-1/2	Severe Acute Respiratory Syndrome Coronavirus 1/2
SD	Standard Deviation
sIA	Screening Interim Analysis
SNRI	Selective Norepinephrine Reuptake Inhibitor
SSRI	Selective Serotonin Norepinephrine Reuptake Inhibitor
SUSAR	Serious Unexpected Suspected Adverse Reaction
UADE	Unanticipated Adverse Device Effect
UP	Unanticipated Problems
US	United States
WT	Wildtype
XR	Extended-Release

### Table of Figures

Figure 1: ACTIV-6 Study Schema .....	20
Figure 2. ACTIV-6 Interim Analysis Schema – Acute Disease .....	21
Figure 3: Operational Structure Diagram .....	60
Figure 4: Survival curve of WT and S1R KO mice.....	85
Figure 5: Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early COVID-19.....	86
Figure 6: Summary of study results for the prospective, nonrandomized observational cohort study with fluvoxamine in participants diagnosed with COVID-19. ....	86
Figure 7. Probability of efficacy for the primary outcome in the ITT and mITT populations of TOGETHER .....	96
Figure 8. Mean (SD) plasma metformin concentrations by treatment and time point after a single daily dose of metformin. ....	105
Figure 9. Metformin systemic (plasma) exposure .....	106

### List of Tables

Table 1: Schedule of Events .....	36
Table 2: ACTIV-6 Sample Size Estimates and Power .....	48
Table 3: Ivermectin Adverse Event Table for Doses $\geq 300$ $\mu\text{g/kg}$ .....	76
Table 4: Ivermectin 400 Dosing Schedule.....	78
Table 5. Fluvoxamine Adverse events occurring in 10-week studies of adult OCD or depression .....	81
Table 6. Fluvoxamine Adverse events that occurred in COVID-19 study participants receiving 300 mg/day for 15 days.....	82
Table 7. Fluticasone Adverse reactions that occurred in $\geq 3\%$ of adults and adolescents with asthma in a 24-week trial. ....	88
Table 8. Ivermectin 600 Dosing Schedule.....	93
Table 9. Montelukast sodium adverse reactions occurring at a higher incidence than placebo, in $\geq 1\%$ of adults and adolescents $\geq 15$ years of age. ....	98
Table 10. Ongoing clinical trials with montelukast.....	101

## 1. Protocol Summary

### 1.1. Synopsis

Title	ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Clinical study phase	III
Rationale	Coronavirus Disease 2019 (COVID-19) is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that first emerged in December 2019 and has since resulted in a global pandemic unseen in almost a century in cases and mortality. Since 2020, advances have been made for treatment of COVID-19 and vaccination for prevention of SARS-CoV-2 infection. However, the pandemic continues to evolve with new variants and surges of infections in different regions of the world, requiring an ongoing evidence-generating clinical trial platform, in particular for the treatment of COVID-19 in the outpatient setting. This platform protocol can serve as an evidence generation system for prioritized drugs, repurposed from other Food and Drug Administration (FDA) indications with an established safety record in humans and preliminary data of efficacy. The ultimate goal is to evaluate if repurposed medications can make participants feel better faster and reduce death and hospitalization.
Acute Disease: Primary Objective	<ul style="list-style-type: none"> <li>To evaluate the effectiveness of repurposed medications [(study drug(s))] in nonhospitalized participants with mild to moderate COVID-19</li> </ul>
Acute Disease: Secondary Objectives	<ul style="list-style-type: none"> <li>To evaluate the clinical outcomes in participants in a study drug arm versus those in the placebo arm</li> <li>To describe symptom resolution in participants in a study drug arm versus those in the placebo arm</li> <li>To describe the quality of life (QOL) in participants in a study drug arm versus those in the placebo arm</li> <li>To compare illness severity trajectories in participants in a study drug arm versus those in the placebo arm</li> </ul>
Acute Disease: Exploratory Objective	<ul style="list-style-type: none"> <li>To describe long-term COVID-19-related symptoms in participants in a study drug arm versus those in the placebo arm</li> </ul>

Post-acute Disease (Appendix G): Primary Objective	<ul style="list-style-type: none"> <li>To compare the risk of Post-Acute Sequelae of SARS-CoV-2 Infection or death (PASCD) at day 180 in participants taking metformin versus placebo</li> </ul>
Post-acute Disease (Appendix G): Secondary Objective	<ul style="list-style-type: none"> <li>To compare the risk of PASCD at day 90 and 120 in participants taking metformin versus placebo</li> </ul>
Post-acute Disease (Appendix G): Exploratory Objective	<ul style="list-style-type: none"> <li>To compare symptom burden in participants taking metformin versus placebo</li> </ul>
Intervention	<p>All interventions will occur in addition to standard of care. Each study drug appendix describes a different study drug and matching placebo. The following arms will be included in each study appendix:</p> <ul style="list-style-type: none"> <li>Study Drug Arm: repurposed medications (see Appendices)</li> <li>Placebo Arm: placebo control</li> </ul> <p><i>While each appendix describes the placebo that matches the study drug, for comparative analysis the control group will comprise eligible, concurrently enrolled participants from all study arms who were assigned to placebo.</i></p>
Study Design	<p>This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within healthcare systems and in community settings where it can be integrated into routine COVID-19 testing programs and subsequent treatment plans. This platform protocol will enroll participants in an outpatient setting with a confirmed positive polymerase chain reaction (PCR) or antigen test for SARS-CoV-2. Each appendix will describe a repurposed medication (study drug) to meet the protocol objectives.</p> <p>When only one study drug/appendix is under study, allocation between study drug and placebo will be 1:1. If multiple study drugs/appendices are under study, participants will also be randomized among the study drugs for which eligibility is confirmed. Since the route of administration of each study drug may differ, the placebos may also differ. To achieve blinding and an equitable randomization probability, a two-step randomization process will be used.</p> <p>In the first step, the participant will be randomized <math>m:1</math> active study drug to placebo, where <math>m</math> is the number of active study</p>

	<p>drugs for which the participant is eligible (note, if the same study drug is tested at multiple doses, each dose will count as one study drug). Then, participants will be randomized among the <math>m</math> study drugs for which they are eligible. Participants will carry their ‘study drug’ versus ‘placebo’ randomization with them into the study drug appendix. In this way, a participant allocated to placebo who is randomized to study drug A will be given the placebo that matches study drug A. This achieves equal probability of exposure among the placebo and active study drugs for which the participant is eligible, and equitable distribution among all study arms for which a participant is eligible. Sites will be informed to which study drug appendix the participant is randomized, but not whether they are allocated to the study drug arm or placebo arm within that appendix.</p> <p>For analysis, concurrent placebo participants who were eligible for the study drug appendix will be pooled. This will result in approximately a 1:1 allocation ratio for any study drug to placebo. If a study drug appendix is stopped for efficacy and becomes standard of care, the active study drug arm may serve as a concurrent placebo for other study drugs.</p> <p>Each study drug appendix will go through Screening Interim Analyses to assess efficacy/futility prior to evaluation of the primary objective. This Screening Interim Analysis provides an innovative approach to evaluate the potential for repurposed drugs to reduce symptom burden and prevent disease progression in the outpatient setting at various points throughout enrollment.</p> <p>Participants will receive complete supply of repurposed medication (study drug) or placebo with length of treatment and amount of study drug/placebo depending on the study drug appendix and arm to which they are randomized.</p> <p>This study is designed so that it can be done completely remotely. However, screening and enrollment may occur in-person at sites and unplanned study visits may occur in-person or remotely, as deemed appropriate by an investigator for safety purposes. Participants will be on-study for up to 180 days, during which they will complete various questionnaires.</p>
Population	Up to 15,000 adults
Study Duration	24 months
Study Location	Up to 280 sites

Inclusion Criteria	<ol style="list-style-type: none"> <li>1. Completed Informed Consent</li> <li>2. Age <math>\geq 30</math> years old</li> <li>3. Confirmed SARS-CoV-2 infection (or reinfection) by any authorized or approved PCR or antigen test collected within 10 days of screening</li> <li>4. Two or more current symptoms of acute infection for <math>\leq 7</math> days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell.</li> </ol>
Exclusion Criteria	<ol style="list-style-type: none"> <li>1. Current or recent (within 10 days of screening) hospitalization for COVID-19 infection</li> <li>2. Current or planned participation in another interventional trial to treat COVID-19, at the discretion of the study principal investigator (PI)</li> <li>3. Current or recent use (within the last 14 days) of study drug or study drug/device combination*</li> <li>4. Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo*</li> <li>5. Known contraindication(s) to study drug including prohibited concomitant medications (see Appendices)*</li> <li>6. Previous or current enrollment in the ACTIV-6 trial</li> </ol> <p><i>*If only one study drug appendix is open at the time of enrollment. If multiple study drug appendices are open, a participant may opt-out of any study drug appendix or be excluded from any study drug appendix based on contraindications listed in the study drug appendix, current use of study drug, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study drug appendices.</i></p>
Sample Size Considerations	<p>This study will enroll up to 15,000 adults, depending on the number of study drug appendices that are added and adjustments to sample size depending on the data.</p> <p><u>Acute disease</u></p> <p>An estimated sample size of approximately 1200 participants per study drug appendix is expected to be sufficient to conclude whether there is meaningful evidence of benefit on the acute disease primary objective.</p> <p>A screening interim analyses (sIA) will occur at n=300 and n=600 to inform termination of the arm, continuation of</p>




	<p>enrollment, or transition to assessment of the primary objective. Formal interim analyses (IAs) of the primary objective are planned at n=300, n=600 and n=900. Review of emerging data will be done according to the schedule of DSMB meetings; no formal interim analyses are expected after n=900.</p> <p>As described in the statistical analysis plan (SAP), the type I error for the primary objective is controlled at <math>&lt; 0.05</math>.</p> <p><u>Post-acute Disease (Appendix G)</u></p> <p>A sample size of 3000 is needed to conclude whether there is meaningful evidence of benefit on the post-acute disease primary objective.</p> <p>A futility analysis on the primary objective of the prevention of PASCD will occur when 600 participants have passed Day 180.</p> <p>As described in the SAP, type I error is controlled at <math>&lt; 0.05</math>.</p>
General Statistical Consideration for Acute Disease Primary Analysis	<p>The primary objective of effectiveness will be determined based on the endpoints of hospitalization/death or time to recovery over 28 days, the choice of which will be specified per appendix. The choice will be documented prior to interim analyses or prior to unblinding. The choice will be guided by emerging data on study drugs in the platform and on overall event rates in the trial, as well as external drivers, such as case rates, availability of other effective therapies, and vaccine effectiveness.</p> <p>The outcomes of interest for this platform (symptoms, hospitalization, and mortality) are collected using a web-assisted symptom diary according to the schedule in <a href="#">Table 1</a>. Symptoms will be graded on an ordinal scale as none, mild, moderate, or severe.</p> <p>The odds of hospitalization or death will be used to draw conclusions about clinical events. Time to recovery, measured as the time to achieving three consecutive days of self-reported symptom freedom, will be used to draw conclusions about symptom burden.</p> <p>The primary analysis will be implemented separately for each study drug, where the matching placebo arm will consist of concurrently randomized participants that meet the inclusion and exclusion criteria for that study drug appendix. A modified intention to treat (mITT) approach will be used for primary analyses; all participants who receive study drug will be included as assigned. It is possible that the delivery of medications (placebo or study drug) does not occur (failure of delivery, participant death, or participant withdrawal); this will result in exclusion of the participant for the</p>

	<p>mITT analysis. All available data will be used to compare each study drug versus placebo control, regardless of post-randomization adherence to study protocols.</p>
Independent Data Monitoring Committee (IDMC)	<p>Frequent IDMC reviews will be conducted to ensure the safety of study participants and evaluate the accumulating endpoint data by treatment group. Regular IDMC meetings will monitor the following parameters at a minimum:</p> <ul style="list-style-type: none"> <li>• Recruitment progress</li> <li>• Enrollment overall and by subgroups</li> <li>• Adherence, retention, and status of data collection</li> <li>• Serious adverse events</li> <li>• Assessment for futility</li> <li>• Probability for benefit across endpoints</li> </ul>
Interim Analysis	<p>Interim analyses (IA) will be performed per study drug appendix, after approximately every 300 participants (~150 in study drug arm and ~150 in placebo arm) have completed the Day 14 Visit. Placebo control participants contributing to this count will be drawn from across study drug appendices, and will include participants who were eligible for the study drug appendix of interest regardless of final study drug arm allocation. The following decision thresholds will be checked during IA(s):</p> <ol style="list-style-type: none"> <li>i) Screening IA (n=300):             <ol style="list-style-type: none"> <li>a. The study drug is found to have benefit (efficacy). Study drug appendix will proceed to acute disease primary objective IA at n=300. <i>Note: this is also a check for harm as all assessments are two-tailed.</i></li> <li>b. The study drug is not found to have benefit, enrollment continues in the study drug appendix and sIA is repeated at n=600.</li> </ol> </li> <li>ii) Screening IA (n=600):             <ol style="list-style-type: none"> <li>a. It would be futile to attempt to show a benefit of the study drug based on the predicted probability of success (PPOS) and other factors. The study drug appendix will be terminated.</li> <li>b. Futility is not determined. Study drug appendix will proceed to acute disease primary objective IA at n=600.</li> </ol> </li> <li>iii) Acute Disease Primary Objective IA (n=300): if the criteria for proceeding to the acute disease primary objective are met when n=300, an acute disease primary objective IA will be conducted</li> </ol>


	<p>for the acute disease primary objective when n=300. The following decisions will be assessed:</p> <ul style="list-style-type: none"> <li>a. The study drug is found to have benefit (efficacy), the study drug appendix will be terminated as the acute disease primary endpoint has been met.</li> <li>b. It would be futile to attempt to show a benefit of the study drug based on the PPOS and other factors. The study drug appendix will be terminated.</li> <li>c. Efficacy/futility is undeterminable, enrollment will continue in the study drug appendix and the acute disease primary objective IA will be assessed at n=600.</li> </ul> <p>iv) Acute disease Primary Objective IA (n=600, 900): if the criteria for proceeding to the acute disease primary objective IA are met when n=600 or n=900, an acute disease primary objective IA will be conducted. The following decisions will be assessed:</p> <ul style="list-style-type: none"> <li>a. The study drug is found to have benefit (efficacy), the study drug appendix will be terminated as the acute disease primary endpoint has been met.</li> <li>b. It would be futile to attempt to show a benefit of the study drug based on the PPOS and other factors. The study drug appendix will be terminated.</li> <li>c. Efficacy/futility is undeterminable, enrollment will continue in the study drug appendix and the acute disease primary objective will be assessed after another 300 participants have been enrolled, or until n=900, and then again when n=3000.</li> </ul> <p>v) Interim analyses beyond n=900: subsequent to planned interim analyses, the evaluation of continuation of a study arm will consider achieving the primary objective, the secondary objective of preventing PASC, and any external stakeholder evidentiary needs with evaluation according to the schedule of DSMB meetings.</p> <p>Post-acute Disease (Appendix G)</p> <ul style="list-style-type: none"> <li>i) Secondary Objective IA (n=600 passing Day 90): A futility analysis on the PASCD endpoint will be conducted when 600 participants have passed day 90 under the assumption of accrual to n=3000.</li> </ul> <p>A posterior probability of meaningful benefit for a study drug in comparison to the placebo control of greater than the appendix-specified threshold will result in a declaration of overall superiority.</p>
--	--

	A PPOS when $n=3000$ or less than the appendix-specified threshold will result in a declaration of futility.
--	--

## 1.2. Schema



**Figure 1: ACTIV-6 Study Schema**



**Figure 2. ACTIV-6 Interim Analysis Schema – Acute Disease**

## **2. Introduction**

### **2.1. Study Rationale**

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that first emerged in December 2019 and has since caused a global pandemic unseen in almost a century with respect to the number of cases and overall mortality.[1, 2] The clinical disease related to SARS-CoV-2 is referred to as Coronavirus Disease 2019 (COVID-19). Since 2020, advances have been made for treatment of COVID-19 and vaccinations for prevention of SARS-CoV-2 infection, through emergency use authorization or FDA approval.[3-8] However, the pandemic continues to evolve with new variants and surges of infections in different regions of the world, requiring an ongoing evidence-generating platform, in particular for the treatment of COVID-19 infection in the outpatient setting. This platform protocol operates in addition to usual care and can serve as an evidence generating system for prioritized drugs repurposed from other indications with an established safety record and preliminary evidence of clinical efficacy for the treatment of COVID-19 and post-acute sequelae of (PASC). The ultimate goal is to evaluate if repurposed medications can make participants feel better faster and reduce death, hospitalization, and PASC.

### **2.2. Background**

In December 2019, numerous patients in Wuhan, China were diagnosed with pneumonia caused by an unknown virus. By January 7, 2020, Chinese scientists had isolated SARS-CoV-2. This is a novel betacoronavirus closely related to severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1).[2] In the subsequent months the spread of the virus led to a global pandemic. As of February 7, 2022 there were approximately 395,540,912 confirmed COVID-19 cases resulting in 5,741,726 deaths worldwide.[1]

The virus continued to spread despite social distancing and masking measures, vaccination campaigns/requirements, and travel restrictions. As the pandemic progressed and social distancing, masking, and travel restrictions were lifted, the virus continued to spread. COVID-19 vaccinations have been distributed and administered globally; however, new SARS-CoV-2 strains continue to emerge, with potential for reduced monoclonal antibody therapeutic and vaccine efficacy.[9] As new strains have emerged that confirm transmission, infection, and even severe disease after vaccination is possible, highlighting the need to establish treatment regimens despite vaccination availability. Furthermore, acceptance and uptake of booster shots has been lower than uptake of the initial vaccination series, further justifying the need for safe and effective therapies. Thus, there remains a need to identify safe and efficacious treatments that can be administered in the outpatient setting.

As of February 2022, multiple clinical trials have been reported, providing guidance to clinical providers on management of COVID-19, particularly in the hospital setting. Various drugs, including monoclonal antibodies and antivirals, have been authorized or approved by the FDA for use in the inpatient and outpatient setting for treatment of COVID-19. Multiple repurposed immunomodulatory agents are clinically used for the treatment of severe COVID-19 in the inpatient setting. Thus, multiple medications have been reported to improve clinical disease and, in some cases, mortality.[10, 11] Few of these are therapies that can be administered at home and few have been studied for PASC.

### **2.3. Benefit/Risk Assessment**

The risks for participation in this study include taking study drug (see Appendices) and loss of confidentiality. There may be some benefit to the participant if the therapy is effective against COVID-19 and/or PASC.

#### **2.3.1. Risk Assessment**

Loss of confidentiality risks: There is a potential risk of loss of confidentiality. Every effort will be made to protect the participant's confidential medical information, but this cannot be guaranteed. Clinical information will not be released without written permission of the participant, except as necessary for monitoring by the IRB, FDA, National Institutes of Health (NIH), Office for Human Research Protections (OHRP), other local, US, and international regulatory authorities/entities as part of their duties.

Risk lowering measures: Study procedures to manage and minimize risks include careful selection of the participants and monitoring over time to check on participants' health. Additional guidance to manage any risks or any change to the risk to the participant based on emerging data will be provided to the study teams, as needed. In addition, an Independent Data Monitoring Committee (IDMC) will monitor safety of the participants throughout the study.

#### **2.3.2. Benefit Assessment**

Participants who randomize to a study drug arm may benefit from study drug administration. There is no direct benefit to participants randomized to the placebo arm apart from participating in generating evidence that may ultimately support treatment for SARS-CoV-2 infection and its complications. In addition, they will benefit from involvement with the team following their health status during the study. The knowledge gained will be a benefit to others in the future.

### 3. Objectives and Endpoints

#### 3.1. Acute disease

Objectives	Outcome Measurements	Reported Endpoints
Primary		
To evaluate the effectiveness of repurposed medications [(study drug(s)] in nonhospitalized participants with mild to moderate COVID-19	<ul style="list-style-type: none"> <li>• Hospitalization or death by Day 28</li> <li>• Time to recovery over 28 days, wherein time to recovery is the third day of three consecutive days of self-reported symptom freedom</li> </ul>	Odds ratio (OR) for clinical events or hazard ratio (HR) for time to recovery will be used to estimate treatment effect.
Secondary		
To evaluate the clinical outcomes in participants in a study drug arm versus those in the placebo arm	<ul style="list-style-type: none"> <li>• COVID Clinical Progression Scale on Day 7, Day 14, and Day 28 (see Section 8.2)</li> <li>• Mortality through Day 28</li> <li>• Hospitalization, urgent care visit, emergency room visit through Day 28</li> </ul>	<p>The following model-assisted endpoints will be reported for the COVID Clinical Progression Scale:</p> <ul style="list-style-type: none"> <li>• The OR describing the difference in clinical progression at each measured time point</li> <li>• The HR describing the difference in time to hospitalization or death</li> </ul> <p>The following endpoints for the composite of medically assisted care will be directly assessed and reported:</p> <ul style="list-style-type: none"> <li>• Time to first urgent care, emergency care, hospitalization or death</li> </ul>
To describe symptom resolution in participants in a study drug arm versus those in the placebo arm	Symptom resolution, defined as three consecutive days without symptoms	Time to symptom resolution



To describe the quality of life (QOL) in participants in a study drug arm versus those in the placebo arm	Modified Patient-Reported Outcomes Measurement Information System (PROMIS)-29 at baseline, Day 7, Day 14, Day 28, Day 90, and Day 120 <sup>1</sup> Follow-up	<ul style="list-style-type: none"> <li>• Odds ratios (ORs) specific to days 7, 14, 28, 90, and 120<sup>1</sup></li> <li>• The OR in QOL scores at each time point</li> </ul>
To compare illness severity trajectories in participants in a study drug arm versus those in the placebo arm	Ordinal outcome including symptom severity, hospitalization, and death measured daily for 14 days	<ul style="list-style-type: none"> <li>• Difference in mean time unwell</li> <li>• Mean days of benefit</li> </ul>
Exploratory		
To describe long-term COVID-19-related symptoms in participants in a study drug arm versus those in the placebo arm	Symptom occurrence, type, and severity at Day 90, Day 120 <sup>1</sup> , or Day 180 <sup>1</sup> Follow-up	Directly measured mean and median symptom count and QOL score at Day 90, Day 120 <sup>1</sup> , or Day 180 <sup>1</sup> in study drug arm(s) versus placebo

### 3.2. Post-acute disease<sup>1</sup> (Appendix G)

Objectives	Outcome Measurements	Reported Endpoints
Primary		
To compare the risk of Post-Acute Sequelae of SARS-CoV-2 Infection or death (PASCD) at day 180 in participants taking metformin versus placebo	<ul style="list-style-type: none"> <li>• Patient reported symptom burden</li> <li>• Mortality status through day 180</li> </ul>	The difference in risk of PASCD at day 180 between groups
Secondary		
To compare the risk of PASCD at days 90 and 120 in participants taking metformin versus placebo	<ul style="list-style-type: none"> <li>• Mortality status through day 180</li> <li>• Patient reported symptom burden</li> </ul>	<ul style="list-style-type: none"> <li>• The difference in risk of PASCD at days 90 and 120 between groups</li> <li>• The risk ratio of PASCD at days 90, 120, and 180 between groups</li> </ul>

<sup>1</sup> Day 180 is applicable only for participants who were consented to the study after protocol v7.0 was implemented; Day 120 is applicable only for participants consented under protocol v6.0; Day 90 was the final follow-up day for Ivermectin 400, Ivermectin 600, Fluvoxamine Maleate, and Fluticasone Furoate.

Exploratory		
<p>To compare symptom burden in participants taking metformin versus placebo</p>	<ul style="list-style-type: none"><li>• PASC Symptom Questionnaire</li></ul>	<ul style="list-style-type: none"><li>• The difference between metformin and placebo responses for 14 symptoms<ul style="list-style-type: none"><li>○ Fatigue</li><li>○ Post-exertional malaise</li><li>○ Weakness (arms/legs)</li><li>○ Pain (limbs)</li><li>○ Faintness</li><li>○ Gastrointestinal upset</li><li>○ Color changes to skin</li><li>○ Dry mouth</li><li>○ Concentration</li><li>○ Confusion</li><li>○ Forgetfulness</li><li>○ Focus</li><li>○ Mental Clarity</li><li>○ Overall health</li></ul></li></ul>

## Study Design

Refer to Section 1.2 for the Study Schema.

This study includes an innovative screening approach using sIAs to make decisions about dropping ineffective agents quickly, or to accelerate study of potentially effective agents. Each study drug appendix will go through sIAs to assess efficacy/futility prior to evaluation of the primary objective. This sIA provides an innovative approach to evaluate the potential for repurposed drugs to reduce symptom burden and prevent disease progression at various points throughout enrollment in a broad population.

### 3.3. Overall Design

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within healthcare systems and in community settings where it can be integrated into routine COVID-19 testing programs and subsequent treatment plans. The platform protocol will enroll participants with mild to moderate COVID-19 in an outpatient setting with a confirmed positive polymerase chain reaction (PCR) or antigen test for SARS-CoV-2 infection. Each appendix will describe a repurposed medication (study drug arm) that is sized to meet the master protocol objectives.

Participants will be randomized to one of the study drug appendices that are actively enrolling at the time of randomization. Study drug appendices may be added or removed according to adaptive design and/or emerging evidence. When there are multiple study drug appendices available, randomization will occur based on appropriateness of each drug for the participant as determined by the study protocol and investigator and participant equipoise. Each participant will be required to randomize to at least one study drug versus placebo. The probability of placebo to treatment will remain the same regardless of eligibility decisions.

Eligible participants will be randomized (1:1), in a blinded fashion, to either the study drug arm or placebo arm in addition to standard of care, when one active drug is on the platform or when a participant is only eligible for one of the active drugs on the platform. As additional study drug appendices are added, the randomization will be altered to leverage placebo data across arms. If a study drug is offered at two doses, each dose will be treated as separate study arm. If a participant is eligible for 1 study arm, they have a 1:1 chance of receiving an active study drug. If a participant is eligible for two study arms, they have a 2:1 chance of receiving an active study drug, for 3 arms it is 3:1, for 4 arms it is 4:1, and so on. This is because each participant assigned to a placebo group is shared among all appendices, and the goal is that within appendices the allocation probability to study drug versus placebo is 1:1. Participants will receive a complete supply of repurposed medication (study drug) or placebo with the quantity depending on the study drug/placebo to which they are randomized.

All study visits are designed to be remote. However, screening and enrollment may occur in-person at sites and unplanned study visits may occur in-person or remotely, as deemed appropriate by the site investigator for safety purposes. Participants will be asked to complete questionnaires and report safety events during the study, according to [Table 1](#). Participants will be prompted by the online system to report safety events and these will be reviewed and confirmed via medical records and site staff, as necessary.

**3.4. End of Study Definition**

A participant is considered to have completed the study if he/she has completed the applicable Long-term Follow-up assessments, refer to [Table 1](#).

The end of the study is defined as the date of the last follow-up of the last participant in the study. Data from interim analyses or recommendations by the IDMC may result in protocol modifications or early termination of the study.

#### **4. Study Population**

All Eligibility Criteria will be obtained per participant.

##### **4.1. Inclusion Criteria**

1. Completed Informed Consent
2. Age  $\geq$  30 years old
3. Confirmed SARS-CoV-2 infection (or reinfection) by any authorized or approved PCR or antigen test collected within 10 days of screening
4. Two or more current symptoms of acute infection for  $\leq$  7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell

##### **4.2. Exclusion Criteria**

1. Current or recent (within 10 days of screening) hospitalization for COVID-19 infection
2. Current or planned participation in another interventional trial to treat COVID-19, at the discretion of the study principal investigator (PI)
3. Current or recent use (within the last 14 days) of study drug or study drug/device combination\*
4. Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo\*
5. Known contraindication(s) to study drug including prohibited concomitant medications (see Appendices)\*
6. Previous or current enrollment in the ACTIV-6 trial

*\*If only one study drug appendix is open at the time of enrollment. If multiple study drug appendices are open, a participant may opt-out of any study drug appendix or be excluded from any study drug appendix based on contraindications listed in the study drug appendix, current use of study drug, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study drug appendices.*

##### **4.3. Recruitment and Engagement**

###### **4.3.1. Participant Recruitment**

Participants who are eligible based on positive SARS-CoV-2 PCR or antigen test will be identified by participating sites or will self-identify to a central study hotline(s) and be referred to the closest site. Site investigators, or their designee, may contact eligible participants to introduce the study and discuss study participation.

###### **4.3.2. Participant Engagement**

Participants will be engaged in the study through multiple channels. This includes, but is not limited to, ongoing participation in other registries partnering with ACTIV or healthcare systems. Additionally, participant engagement will include:

- compensation for participants who complete the applicable Final Visit (Day 90, 120, or 180);
- creating a study-wide ACTIV-6 Advisory Group;
- developing participant-centered approaches that recognize the needs and preferences of COVID-19 survivors locally and nationally; and
- multifaceted approaches that combine engagement tools, leverage the online system, use of social media, and representative COVID-Participants.

#### **4.3.3. Participant Randomization Process**

This trial is a double-blind, placebo-controlled trial. Participants and investigators will be blinded. A participant who is eligible for  $m$  study drug arms/appendices will be randomized  $m:1$  study drug to placebo (**Figure 1**). The participant will then be randomized with  $1/m$  probability to each of the study drug appendices. A participant entering a study drug appendix carries their study drug or placebo designation with them and will get either the study drug or matching placebo. Participants who receive placebo will be pooled across study drug arms for those study drug arms/appendices that the participant is eligible. This reduces overall sample size by facilitating sharing of data from concurrent controls while maintaining a 1:1 allocation to study drug or placebo within an appendix. Randomization sequences will not be pre-generated. Given the adaptive nature of the trial and the unknown number of study drug appendices, arm assignment will be implemented at the time of confirming eligibility for randomization using a random number generator. The participant eligibility criteria will be checked for each study drug appendix, and the randomization probabilities will be set. The two step procedure will then occur, and the assignment to both study drug appendix and study drug versus placebo will be made. The participant and study teams will know which study drug appendix the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.

The participant, treating clinicians, and study personnel will remain blinded to study drug versus placebo assignment until after the database is locked and blinded analysis is completed. Only the biostatistical team who is preparing closed IDMC interim reports will be unblinded. Specifically, study drug/placebo will be dispensed with packaging and labelling that would blind treatment assignment. Unblinding will occur only if required for participant safety or treatment at the request of the treating clinician. Refer to the Manual of Procedures (MOP) for further details.

#### **4.4. Screen Failures**

Screen failures are defined as participants who consent to participate in the clinical study, who fulfill inclusion and exclusion criteria, but are not subsequently randomized. Screen failures also include participants who consent, then on review by the site, are found to be ineligible for the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities.

Individuals who are considered screen failures may not be re-screened.

**4.5. Enrollment**

Participants who are randomized and receive study drug/placebo will be considered enrolled. Participants who are randomized, but do not receive study drug/placebo for any reason (e.g., study drug lost in the mail, death prior to receipt of study drug, participant withdrawal prior to receipt of study drug), will not be considered enrolled on the study and will be identified as *randomized not enrolled*.

Receipt of study drug will be defined as evidence that the study drug was delivered to the address of record.

## **5. Study Drug(s)**

### **5.1. Repurposed Medication Treatments**

See Appendices

### **5.2. Placebo**

See Appendices

### **5.3. Study Drug Accountability**

Use of study drug will be tracked via the online system, call center, or sites. Participants will dispose of any unused study drug as they would normally when stopping a medication.

### **5.4. Concomitant Therapy**

Select concomitant medications of interest that the participant is receiving at the time of enrollment or receives during the course of the study will be recorded along with dosing information. Select concomitant medications of interest include the following and will be verified at each remote visit by designated study personnel:

- Any therapeutics that is thought to have potential or purported COVID activity including hydroxychloroquine
- Antibiotics
- Antifungals
- Antiparasitic
- Antivirals including HIV protease inhibitors and ribavirin
- Immunosuppressants including steroids
- Angiotensin-converting-enzyme (ACE)/angiotensin II receptor blockers (ARB)/angiotensin receptor neprilysin inhibitor (ARNI)
- Statin
- Anticoagulants and antiplatelets
- COVID-19 vaccine (before, during, or after study intervention)

Refer to the MOP for more details on concomitant therapy. Refer to the appendices for contraindicated medications for each of the study drugs.

### **5.5. Intervention After the End of the Study**

No additional study drug will be provided to the participant following completion of the study.



## **6. Participant Withdrawal/Termination and Study Termination**

### **6.1. Participant Withdrawal/Termination**

Participants will be followed until participant closeout, withdrawal of consent, or death.

A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons. This is expected to be uncommon.

Those who request withdrawal from the study will be asked to continue on study follow-up with limited participation through the Final Visit (Section 8.1.4). Limited participation may include a call(s) to assess safety at study visits following withdrawal.

If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.

### **6.2. Premature Termination or Suspension of the Study**

The study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification will be provided documenting reason for study suspension or termination to the investigators, funding agency, and regulatory authorities, as appropriate. Circumstances that may warrant termination or suspension include, but are not limited to:

- Determination of unexpected, significant, or unacceptable risk to participants
- Insufficient compliance to protocol requirements
- Data that are not sufficiently complete and/or evaluable
- Determination of futility after a sufficient time has passed for accrual of the primary and secondary outcomes
- Recommendation by the IDMC

### **6.3. Lost to Follow-up**

Participants will be asked for proxy contacts to assess vital status and/or other clinical events, including safety, if a participant fails to provide the information. Provision of proxy information is not required for study participation. A participant will be considered lost to follow-up if he or she repeatedly fails to complete study assessments/procedures as outlined below and neither the participant nor the participant's proxy can be contacted by the study site.

The following actions must be taken if a participant fails to provide baseline information, if he or she fail to complete daily symptom reporting by midnight the day after receiving the first dose of study drug/placebo (Day 2), if he or she miss one daily symptom reporting during Days 3 to 14, if he or she miss either the Day 14 or Day 28 Remote Visits, and/or he or she fail to complete the applicable Final Visit assessments:

- The site or call center must attempt to contact the participant and counsel the participant on the importance of completing study assessments/procedures.
- The site or call center will contact the participant's proxy to assess vital status and/or other clinical or safety events.
- The site or call center will attempt to collect all missing survey responses.

- Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact with the participant (where possible, three telephone calls and, if necessary, a certified letter to the participant's last known mailing address or local equivalent methods). These contact attempts should be documented in the participant's research record.
- Online obituary search.
- Should the participant continue to be unreachable, they will be considered lost to follow-up.

## **7. Study Assessments and Procedures**

Screening and eligibility confirmation will be participant-reported. A positive SARS-CoV-2 test result must be verified prior to randomization (refer to the MOP for details). Sites will be responsible for notifying the coordinating center for participant withdrawals, lost to follow-up, permanent cessation of study drug, study drug dose modifications (if allowed, per Appendix), or change in vital status. Data will be collected directly from the participant and supported by medical records, as needed.

## 7.1. Schedule of Events

**Table 1: Schedule of Events**

	Screening	Intervention Period		Follow-up Period						Final Visit	Unplanned Study Visit
Day	Within 7 days of Day 1	Day 1	Days 2 - 14	Day 15 - 20	Day 21 ± 2	Day 22 - 27	Day 28 + 5	Day 90 <sup>2</sup> + 5	Day 120 <sup>2</sup> + 5	Day 180 <sup>2</sup> + 7	
ACTIV-6 Trial											
Consent	X										
Demographic Information	X										
Eligibility criteria confirmed	X										
Randomization	X										
Receipt of study drug or placebo		X									
Continued use study drug		Continuous <sup>3</sup>									
Clinical Assessments											
Abbreviated medical history	X										
Self-reported Pregnancy	X <sup>4</sup>										
Concomitant Therapy	X	X <sup>5</sup>	X <sup>5</sup>								
Remote Visit			X <sup>6</sup>				X				
Drug Adherence		X	X								
COVID-19 Outcomes		X	X <sup>8</sup>		X		X	X	X	X	
Symptom Reporting	X <sup>7</sup>	X	X <sup>7</sup>	X <sup>7</sup>	X <sup>7</sup>	X <sup>7</sup>	X <sup>7</sup>	X	X	X	
PASC Symptom Questionnaire										X	
QOL Questionnaire	X		X <sup>8</sup>				X	X	X	X	
At-home pulse oximetry			X <sup>9</sup>								
Columbia-Suicide Severity Rating Scale (C-SSRS)			X <sup>10</sup>								
Hypoglycemia Reporting			X <sup>11</sup>								
Safety Assessment <sup>12</sup>		Continuous via online system and medical record review									X

<sup>2</sup> Day 180 is applicable only for participants who were consented after protocol v7.0 was implemented; Day 120 is applicable only for participants consented on protocol v6.0; Day 90 was the final follow-up day for Ivermectin 400, Ivermectin 600, Fluvoxamine Maleate, and Fluticasone Furoate

<sup>3</sup> Refer to study drug appendix for length of study drug administration.

<sup>4</sup> Only for enrollment in Study Drug Appendices that have pregnancy listed as a contraindication for females of childbearing potential. Participants will self-report pregnancy using the Pregnancy Reasonably Excluded Guide.

<sup>5</sup> Review only during study drug/placebo administration if contraindicated medications provided for the study drug arm, per Appendix.

<sup>6</sup> Day 14 only.

<sup>7</sup> Daily symptom reporting; continued daily beyond day 14 through day 28 until symptoms resolve for  $\geq 3$  consecutive days. All participants will complete symptom reporting on Days 21 and 28, regardless of symptom resolution.

<sup>8</sup> Day 7 and 14 only.

<sup>9</sup> Day 3, 7, and 14 only.

<sup>10</sup> At Day 7 and 14 for participants enrolled in Appendix E – Fluvoxamine Maleate 100.

<sup>11</sup> At Day 14 for participants enrolled in Appendix G – Metformin Hydrochloride Immediate-Release.

<sup>12</sup> Participant's medical record will be reviewed to confirm Serious Adverse Events (SAEs), Unanticipated Adverse Device Events (UADEs) [as applicable], and Events of Special Interest (ESIs).

### 7.1.1. Screening

The following events will occur at Screening:

- Consent: Participants will be consented either via an e-consent process or paper process. The consent process should be done in accordance with local and central IRB regulations. Phone consenting may be facilitated through the e-consent or paper process.
- Demographic information will be collected including, but not limited to, age, sex, race, ethnicity, and occupation
- Eligibility criteria confirmation by the participant via the online system or by site staff via a paper process
- Abbreviated medical history
- Self-reported pregnancy, for women of childbearing potential (**only for enrollment in Study Drug Appendices that include pregnancy as a contraindication**)
- Concomitant therapy
- Symptom reporting, daily during screening period
- QOL questionnaire
- Randomization (see Section 5.3.3)

### 7.1.2. Intervention Period

The following events will occur during the Intervention Period, starting with receipt of study drug/placebo:

#### Day 1:

- Receipt of study drug or placebo
- Study drug self-administration (see Appendices for specific study drug/placebo administration)
- Concomitant therapy
- Drug adherence questionnaire
- COVID-19 Outcomes
- Symptom reporting
- SAE, UADE (as applicable), and ESI collection

#### Days 2 – 14:

- Study drug self-administration (see Appendices for specific study drug/placebo administration)
- Concomitant therapy, including contraindicated medications provided for the study drug arm, per Appendix, during study drug/placebo administration.
- Remote visit (**Day 14 only**)
- Drug adherence questionnaire, daily
- COVID-19 Outcomes (**Day 7 and 14 only**)
- Symptom reporting, daily
- QOL questionnaire (**Day 7 and 14 only**)
- At-home pulse oximetry readings (**Day 3, 7, and 14 only**)

- C-SSRS (**Day 7 and 14 for Appendix E – Fluvoxamine Maleate 100 only**)
- Hypoglycemia reporting (**Day 14 for Appendix G – Metformin Hydrochloride Immediate-Release only**)
- SAE, UADE (as applicable), and ESI collection

### 7.1.3. Follow-up Period

#### Day 15 – 20:

- Symptom reporting, daily from Day 14 for participants who have **not** yet reported three consecutive days of no symptoms. Participants who experience three days of improvement before Day 14 but who then experience symptoms again will not be followed daily.
- SAE, UADE (as applicable), and ESI collection

#### Day 21 ± 2 days:

- COVID-19 Outcomes
- Symptom reporting
- SAE, UADE (as applicable), and ESI collection

#### Day 22 – 27:

- Symptom reporting, daily from Day 14 for participants who have **not** yet reported three consecutive days of no symptoms. Participants who experience three days of improvement before Day 14 but who then experience symptoms again will not be followed daily.
- SAE, UADE (as applicable), and ESI collection

#### Day 28 + 5 days:

- Remote visit
- COVID-19 Outcomes
- Symptom reporting
- QOL questionnaire
- SAE, UADE (as applicable), and ESI collection

#### Day 90 + 5 days:

- COVID-19 Outcomes
- Symptom reporting
- QOL questionnaire
- SAE, UADE (as applicable), and ESI collection

The Day 120 + 5 days Follow-up visit is only applicable for participants consented on protocol v6.0 or later and will include the following:

- COVID-19 Outcomes
- Symptom reporting
- QOL questionnaire

- SAE, UADE (as applicable), and ESI collection

#### 7.1.4. Final Visit

Depending on when the participant was consented, the Final Visit may have occurred at Day 90 or Day 120. Following implementation of protocol v7.0, Day 180 + 7 days will serve as the Final Visit. The Final Visit will include the following:

- COVID-19 Outcomes
- Symptom reporting
- Post-acute Sequelae of SARS-CoV-2 Infection (PASC) Symptom Questionnaire (**Day 180 participants only**)
- QOL questionnaire
- SAE, UADE (as applicable), and ESI collection

#### 7.2. Clinical Assessments

Abbreviated Medical History: smoking status, estimated body mass index (BMI)/obesity, pre-existing underlying lung disease (e.g., chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis), underlying immunosuppression (transplant, malignancy, human immunodeficiency virus (HIV), autoimmune disease), medical conditions that may increase risk of COVID-19 infections or complications (e.g., diabetes, cardiovascular disease, hypertension, chronic kidney disease), venous thromboembolism, chronic liver disease, COVID-19 vaccination status

Concomitant Medications of Interest: Concomitant medications of interest, including study drug specific contraindicated medications, will be collected. Refer to Section 6.4 for concomitant medications of interest and to the study drug specific appendices for contraindicated medications.

Self-reported Pregnancy: Participants will be asked to self-report pregnancy, as needed, per Study Drug Appendix. The 3-item “Pregnancy Reasonably Excluded Guide” will be used to assess pregnancy at screening. The “Pregnancy Reasonably Excluded Guide” uses traditional and World Health Organization criteria to exclude pregnancy via participant self-report.[12] Refer to the MOP for details.

Remote Visit: Designated study personnel will contact the participant directly via a phone call or other form of direct contact (e.g., text or e-mail survey) in order to conduct study assessments, including, but not limited to, COVID-19 outcomes, drug adherence (at Day 14), and safety events. A missed remote visit will be considered a protocol deviation (non-major). If a participant misses a remote visit, site study staff should take immediate action to contact the participant, per Section 7.3 follow-up processes. Refer to the MOP for details.

Drug Adherence: Adherence to the study drug administration schedule will be collected via the online system and confirmed at the Day 14 remote visit.

COVID-19 Outcomes: The COVID-19 outcomes for this trial are based on the World Health Organization’s Ordinal Scale for Clinical Improvement and will be collected via the online system and from the medical record.[13] The following outcomes will be assessed as part of the COVID Clinical Progression Scale:

0. No clinical or virological evidence of infection
1. No limitation of activities
2. Limitation of activities
3. Hospitalized, no oxygen therapy
4. Hospitalized, on oxygen by mask or nasal prongs
5. Hospitalized, on non-invasive ventilation or high-flow oxygen
6. Hospitalized, on intubation and mechanical ventilation
7. Hospitalized, on ventilation + additional organ support – pressors, RRT, ECMO
8. Death

Symptom Reporting: Symptoms and symptom-related responses will be reported by the participant via the online system. Additional symptom reporting may occur from the sites, as available. Each of pre-defined symptoms will be assessed on an ordinal severity scale of none, mild, moderate, and severe. The following symptoms will be collected:

- Overall symptom burden
- Fatigue
- Dyspnea - shortness of breath or difficulty breathing at rest or with activity
- Fever
- Cough
- Nausea
- Vomiting
- Diarrhea
- Body aches
- Sore throat
- Headache
- Chills
- Nasal symptoms
- New loss of sense of taste or smell
- Other COVID-related symptom

Post-acute Sequelae of SARS-CoV-2 Infection (PASC) Symptom Questionnaire: COVID-19 has affected many lives through lingering symptoms, often debilitating long after acute SARS-CoV-2 infection. The syndrome of PASC is a chronic condition present in up to 80% of infected, hospitalized patients and 40% to 70% of non-hospitalized patients. [14-18] The PASC Symptom Questionnaire includes symptoms that are associated with PASC and asks for severity (mild/moderate/severe) related to any symptoms identified by the participants.

At-home pulse oximetry measurements: Participants will provide pulse oximetry readings using a study-provided FDA-approved pulse oximeter. Two consecutive pulse oximetry readings must be reported at each required time point. Day 3, 7, and Day 14 are study-required time points for pulse oximetry readings. Participants can report pulse oximetry readings at other times throughout the study, at their own discretion.



### 7.3. Quality of Life Questionnaires

The following QOL questionnaire will be used in this study:

- Modified PROMIS-29: PROMIS measures were developed through a collaborative process funded by the NIH.[19] The PROMIS-29 consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance.[20] The PROMIS-29 measures will be modified for this study and will include select questions from each of the seven health domains, refer to the MOP for details.

## **8. Safety Assessments**

### **8.1. Adverse Events and Serious Adverse Events**

An AE is any untoward medical occurrence in humans, whether or not considered drug-related, which occurs during the conduct of a clinical trial. An AE can therefore be any change in clinical status, routine labs, x-rays, physical examinations, etc., that is considered clinically significant by the study investigator.

An SAE or serious suspected adverse reaction or serious adverse reaction as determined by the investigator or the sponsor is an AE that results in any of the following serious outcomes:

- Death
- Life-threatening AE (“life-threatening” means that the study participant was, in the opinion of the investigator or sponsor, at immediate risk of death from the reaction as it occurred and required immediate intervention)
- Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- Inpatient hospitalization or prolongation of existing hospitalization
- Congenital abnormality or birth defect
- Important medical event that may not result in one of the above outcomes, but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious event

Hospitalization for elective treatment of a preexisting condition that did not worsen from baseline does not meet the definition of an SAE. Hospitalization is defined as a stay in the hospital exceeding 24 hours.

An unexpected AE is defined as any AE, the specificity or severity of which is not consistent with the package insert.

#### **8.1.1. Adverse Device Effect (ADE) and Unanticipated Adverse Device Effect (UADE)**

For those repurposed medications that are a part of a combination product, which includes a drug and a device, the following additional definitions will apply.

An ADE is an AE related to the use of an investigational medical device. This includes any AE resulting from insufficiencies or inadequacies in the instructions for use, the deployment, the implantation, the installation, the operation, or any malfunction of the repurposed medical device. This also includes any event that is a result of a use error or intentional misuse.

- Device malfunction – the failure of a device to perform in accordance with the instructions for use or clinical investigative plan.
- User error or intentional misuse – A device is used in a manner that is an act or omission of an act that results in a different medical device response than intended by the manufacturer or expected by the user.

A UADE is any SAE caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or applications (including a supplemental plan or application), or any other unanticipated

serious problem associated with a device that relates to the rights, safety, or welfare of participants.

Unanticipated Adverse Device Effects (UADEs) will include events meeting either A or B as stated below:

A. Events meeting ALL of the following criteria:

- Not included in the relevant appendices or Product Label
- Related to the device per site PI and/or IND sponsor
- Serious (meets any of the following criteria):
  - Is life-threatening illness or injury
  - Results in permanent impairment of a body function or a body structure
  - Necessitates medical or surgical intervention to prevent permanent impairment of a body function or a body structure
  - Results in hospitalization
  - Led to fetal distress, fetal death, or congenital abnormality or birth defect
  - Led to death

*(Permanent means irreversible impairment or damage to a body structure or function, excluding trivial impairment or damage).*

B. Any other unanticipated serious problem associated with the device that relates to the rights, safety, or welfare of participants.

### **8.1.2. Collection Period for AE and SAE Information**

Study participants (and their designated emergency proxies) will be instructed to report ESIs per appendix and Section 9.1.5, SAEs, and UADEs through their access to the study's online system. Each day for 14 days, the participant will be asked to report on their symptoms and health state, including hospitalization and/or other change in health condition. The assessments include specific questions pertaining to ESIs, as well as symptoms and severity, health care visits, medications and a notification to the participant to contact the study team with any concerns or questions. If the participant is still reporting symptoms at Day 14, they will continue to be assessed until they have experienced three consecutive days without symptoms, or until Day 28, whichever is shorter. At Day 28, Day 90, Day 120, and Day 180, participants will complete assessments. Safety reporting will be available to the participant continuously throughout the study, but will only be required at the aforementioned collection points.

The daily and follow-up assessments, as described in the paragraph above, will be monitored and sites will be actively notified of events requiring review, including for reporting that meets criteria for ESIs, SAEs, or UADEs. Refer to the MOP for details. In addition, participants will be invited during assessments to request contact from the study team, or to report any unusual circumstances that might be relevant, if they so wish. Failure to complete daily assessments is also a trigger for review of a possible SAE. A missed assessment on the day after receiving the

first dose of study medication (Day 2) or any day of missed assessments up to Day 14 will prompt a notification to the site to contact the participant.

All participants will be instructed to self-report concerns either via an online event reporting system, by calling the site, or by calling a 24-hour hotline. Participants will have access to event reporting via the online system from the signing of the informed consent form (ICF) until the Final Visit (Day 90, Day 120, or Day 180 depending on the time of consent).

Events of special interest (ESIs) and SAEs will be extracted by site personnel from the participant's medical record if the participant seeks medical care or if hospitalization occurs, each of which notifies the site to conduct follow up.

Medical occurrences that begin before the start of study drug/placebo, but after obtaining informed consent, will not be considered an AE.

Non-serious AEs (or ADEs, as applicable) may be reported by the participant, but will not be further assessed by the site or study personnel unless the event meets the criteria of an ESI.

Events of Special Interest (ESIs), SAEs, and UADEs (as applicable) will be collected from the start of study drug/device combination until the Final Visit (Day 90, Day 120, or Day 180 depending on the time of consent) or until 30 days after the last dose/use of device if participant terminates the study early.

### **8.1.3. Assessing Causality of a Serious Adverse Event**

If an SAE occurs, the site investigator or medical monitor will assess the relationship to study drug by using the following criteria:

- Related:
  - Study drug – there is a temporal relationship between study drug and event onset or the event abates when study drug is discontinued or known to occur with study drug.
  - Device – an event is due to the use of the device and cannot be reasonably explained by an alternative cause.
- Not related: The event has no temporal relationship to study drug (or study device, as applicable) or the AE (or ADE, as applicable) has a much more likely alternate etiology or is due to an underlying or concurrent illness or effect of another drug (or device, as applicable).

### **8.1.4. Reporting and Monitoring of SAEs**

All of the study drugs used in this platform protocol are repurposed medications that are approved for marketing in the US for another medical condition. However, their investigational use for treatment of COVID-19 infection is not an approved indication and will be under an IND and subject to IND regulations in 21 CFR 312. The IND sponsor or designee will review SAEs weekly, and will perform aggregate reviews of SAEs every two weeks. The IND sponsor or her designee will be responsible for determining if the safety reporting criteria are met per 21 CFR 312.32(c)(1)(i)(C) and 21 CFR 312.32(c)(1)(iv) and will notify the Data Coordinating Center (DCC) to prepare an aggregate report for submission to the FDA. An aggregate safety report will

be submitted to FDA as soon as possible, but in no case later than 15 calendar days after the IND sponsor determination. If the IND sponsor determines that an unexpected fatal or life-threatening suspected adverse reaction occurs markedly more frequently in a study drug arm than in the placebo arm, an aggregate safety report will be submitted to the FDA as soon as possible, but in no case later than 7 calendar days after the IND sponsor determination. Information on individual SAEs will be available upon request from the Agency following the submission of any aggregate reports.

Any UADE(s) that the IND sponsor determines is/are reportable will be submitted to the FDA, manufacturer, all reviewing IRBs, and all participating investigators within 10 working days of when the sponsor makes that determination.

If the IND sponsor determines that a UADE presents an unreasonable risk to participants, all investigations or parts of investigations presenting that risk shall be terminated as soon as possible. Termination shall occur not later than 5 working days after the sponsor makes this determination and no later than 15 working days after the sponsor first received notice of the effect.

All hospitalization and death events will be adjudicated (see Section 10.9), any event that is determined to be COVID-19-related will **not** be reportable as an expedited SAE, with the exception of events that are related to study drug and unexpected, which will be reportable regardless of relatedness to COVID-19. All events that are **not** COVID-19-related per the adjudication process will be reviewed by the DCRI Safety Medical Monitor to determine if the event is a reportable SAE.

Individual SAEs and UADEs must be entered into the data system within 24 hours of site awareness. The DCRI Safety Surveillance team will notify pharmaceutical partners of SAEs within 1 business day of their receipt that occur involving the specific appendix of the supplied study drug/placebo, as required. Serious Adverse Events that are related and confirmed unlisted by the DCRI Safety Medical Monitor will be reported to the FDA as SUSARs; as 7-day reports for unexpected fatal or life-threatening adverse reactions and 15-day reports for serious and unexpected adverse reactions. If the IND sponsor, IDMC, or FDA note a clinically important increase in the rate of a SUSAR, the IND sponsor or her designee will notify investigators no later than 15 calendar days after determining that the information qualifies for reporting. The investigator will follow all reportable events until resolution, stabilization or the event is otherwise explained. The DCRI Safety Surveillance Team will follow all SAEs until resolution, stabilization, until otherwise explained.

Pregnancies that occur while on-study will be collected and will not be followed to outcome if outcome occurs beyond the participant's Final Study Visit, however, any associated ESI or SAE should be reported if information can be collected and entered into the EDC. The DCRI Safety Surveillance team will notify pharmaceutical partners of a pregnancy within 1 business day of receipt that occur involving the specific appendix of the supplied study drug/placebo, as required.

#### **8.1.5. Events of Special Interest**

The following are also considered ESIs to the study and will be collected by study personnel via medical record review when concern for ESIs are observed for hospitalized participants:

- Hypoxia, defined as two consecutive pulse oximetry readings  $\leq 93\%$

Each study drug may have a unique list of possible related ESIs. Refer to the relevant appendices.

## **8.2. Unanticipated Problem (UP) and Terminations**

### **8.2.1. Definition of Unanticipated Problem**

The OHRP considers UPs involving risks to participants or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:

- Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the participant population being studied.
- Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research).
- Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

### **8.2.2. Reporting of an Unanticipated Problem**

The site investigator will report UPs for their participants to the DCC. The site may also be required to inform their reviewing IRB about a UP occurring at the local institution. The UP report to the DCC will include the following:

- A detailed description of the event, incident, experience, or outcome
- An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP
- A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP
- The DCC will document and review all UPs. Details of the UP-reporting process will be located in the MOP.

## **9. Statistical Considerations**

The following subsections apply to acute disease and post-acute disease objectives. Where differences exist, the subsection will reference Appendix G.

### **9.1. Statistical Hypotheses**

#### **9.1.1. Primary Hypothesis**

The primary hypothesis for acute disease in this trial is that participants who receive study drug will have reduced disease progression to hospitalization or death and/or more rapid resolution of symptoms as compared to those who receive placebo.

For the post-acute disease hypothesis, see Appendix G, Section [21.7.1](#).

### **9.2. Sample Size Determination**

This study is designed to be analyzed using a Bayesian approach, accepting the possibility of adding and dropping of arms as the trial progresses. There is also the potential for extending accrual in a study drug appendix if there is the potential to demonstrate benefit. Detailed simulations will be used to demonstrate the operating characteristics common to each study drug appendix. Decision thresholds will be set to balance overall power with control of the Type I error rate in the context of the appendix-specific goal.

To aid planning for this trial, symptom count and clinical event data were estimated from participants in a clinical trial with similar inclusion criteria. Data were not collected daily in that study, but evaluations were completed on Day 10 after randomization, which is considered a clinically meaningful point in time. Based on the observed distribution, it is estimated that studies of about  $n=600$  (300 study drug and 300 placebo) will be sufficiently sized to determine whether there is evidence of meaningful benefit per the acute disease primary objective with  $>85\%$  power ([Table 2](#)). Moreover, when a study drug demonstrates overall effectiveness, the planned adaptations to increase targeted accrual for the purpose of demonstrating benefit on clinical events is a reasonable extension within the context of this platform. The final decision thresholds and operating characteristics selected for each appendix, if deviating from the common approach described in the SAP, will be customized in an appendix-specific SAP. An estimated sample size of approximately 1200 participants per study drug appendix is expected to be sufficient to conclude whether there is meaningful evidence of benefit on the primary objective. It is expected that this study will enroll up to 15,000 adults, depending on the number of study drug appendices that are added and adjustments to sample size depending on the data.[21]

For sample size details of post-acute disease, see Appendix G, Section [21.7.1](#).

**Table 2: ACTIV-6 Sample Size Estimates and Power**

OR	Corresponding difference in mean symptom burden	Power			Corresponding Risk Difference in clinical events	Power		
		80%	85%	90%		80%	85%	90%
0.4	2.10	75	86	101	0.025	343	392	459
0.5	1.98	132	150	176	0.021	455	520	608
0.6	1.86	242	277	324	0.017	675	772	903
0.7	1.74	496	567	664	0.012	1004	1148	1343
0.8	1.61	1267	1449	1696	0.009	1652	1889	2211

The sample sizes given are the sample size for the study drug arm only. Placebos will be borrowed across study drug appendices. The total size of the placebo arm will be equal to the size of the study drug arm. The total number of placebos in the trial will depend on eligibility of participants among the study drug appendices and the number of study drugs. The calculations are based on symptom burden, hospitalization, and death at Day 10.

### 9.3. Randomization

See Section 5.3.3 for additional details.

### 9.4. Blinding

The investigators, treating clinicians, and study participants will all remain blinded to study drug versus placebo assignment until after the database is locked and blinded analysis is completed. Only the Investigational Drug Service (IDS) and staff who are handling randomization codes and unblinded members of the biostatistical team who are preparing closed IDMC interim reports will be unblinded. The statistical staff responsible for preparing IDMC reports will not directly interact with the clinical team that delivers care to the study participants. Specifically, study medication will be dispensed with packaging and labelling that would blind treatment assignment. Unblinding will occur only if required for participant safety or treatment at the request of the treating clinician.

The web-based randomization system will include blind-breaking instructions. Participant safety must always be the first consideration in making an unblinding determination. If the investigator decides that unblinding is warranted, the investigator should complete an unblinding request, which will immediately notify the Medical Monitor (see MOP for details).

### 9.5. Populations for Analyses

#### Modified Intention to Treat (mITT) Population:

- All participants who receive study drug/placebo.
- Participants who do not receive study drug, for any reason, will be excluded; while this modifies the intention to treat principle, the failure of delivery of medications from site to participant is not under the control of either investigator nor participants and is expected to occur infrequently and randomly. Similarly, early death of a participant or withdrawal prior to the study drug being received is possible, but unlikely and expected to occur randomly between study drug appendices. All other participants will be included, and they will be analyzed according to which arm they were assigned. Thus, the mITT analysis set includes all participants who were randomized and received the study drug.



### Safety Population:

- The safety population will include those persons in the mITT population who report taking at least one dose of study drug or matching placebo. In the unlikely case a participant receives the incorrect study drug, participants will be grouped according to the treatments that they received.

## **9.6. Statistical Analyses**

The main trial SAP will be finalized prior to the primary analysis. It will include a description of the statistical analyses and detailed simulations used to inform the sample size estimates.

Appendix-specific decisions, such as choice of covariates for the model, and context specific decisions such as deviations in decision making thresholds or in targeted accrual, will be made blinded to data and prior to analyses. Such decisions will be documented in the trial master file.

This section is a brief summary of the planned approach to statistical analyses of the most important endpoints including primary and secondary endpoints.

For statistical analysis details of post-acute disease, See Appendix G, Section [21.7](#).

### **9.6.1. General Considerations**

Baseline demographic and clinical variables will be summarized for each randomized arm of the study. Descriptive summaries of the distribution of continuous variables will be presented in terms of percentiles (e.g., median, 25th and 75th percentiles) along with means and standard deviations. Categorical variables will be summarized in terms of frequencies and percentages. Histograms and boxplots may be used to visualize the data.

If an efficacy signal is observed at  $n=300$  or  $n=600$  following sIA, the trial will enter assessment of the acute disease primary objective. At that time, the pre-determined primary clinical endpoint for the appendix will be evaluated as either clinical events (hospitalization or death) or time to recovery. The unselected endpoint will be reported as part of the secondary objective. Both clinical endpoints will be analyzed using a covariate-adjusted statistical model.

### **9.6.2. Statistical Modeling**

Estimation and inferences about the effect of each study drug versus matching placebo will be made using Bayesian regression methods. For acute disease outcomes, at least 30 events must occur in order to perform inference, if fewer than 30 events occur, the analysis will only be descriptive. For each study drug, the matching placebo arm will consist of concurrently randomized participants that meet the inclusion and exclusion criteria for that study drug. The statistical models are described in detail in the SAP. Briefly, a longitudinal ordinal regression model will be used for the sIA, a logistic regression model will be used for clinical events, and proportional hazards models will be used for time to event analyses. All models will be adjusted for covariates, including baseline symptom severity and time from symptom onset. Covariates will be formally specified prior to an analysis, considering emerging data and changing context.

### **9.6.3. Assessing Effectiveness (Acute Disease Primary Objective)**

The overall effect of each study drug versus matching placebo will be quantified using one of the following two primary endpoints, unless otherwise specified in the appendix: composite clinical

events (hospitalization or death) or time to recovery. The primary endpoint will be defined and documented per study drug appendix prior to the initial IA.

The primary analysis will be implemented separately for each study drug appendix where the matching placebo arm will consist of concurrently randomized participants that meet the inclusion and exclusion criteria for that study drug. Decision thresholds, priors, and meaningful effect sizes may change during the course of the pandemic, as vaccination rates, case rates, and new therapies continue to evolve. Thresholds, effect sizes and priors, that vary during the trial from those described in the main SAP will be documented in the trial master file or other designated document. Prior to any interim or final analysis, all decision thresholds, priors and effect sizes will be confirmed and evaluated using extensive simulations to demonstrate the overall Type I error rate remains below 0.05.

An mITT approach will be used for primary analyses. All available data will be used to compare each study drug versus placebo control, regardless of post-randomization adherence to study protocols.

#### **9.6.4. Acute Disease Interim Analyses (IA), Early Stopping, and Type-I Error Control**

Individual study drugs may require different sample sizes, and the sample sizes may be adjusted based on the results of IA. Therefore, fixed enrollment triggers will be used for IA. An IA will occur after enrollment and completion of 14-day follow-up of approximately every 300 participants in a study arm (150 in study drug arm and 150 in placebo arm). Beyond n=900, IA will occur according the DSMB meeting schedule. Study drug appendices may be stopped early for efficacy or futility (see [Figure 2](#)). Thresholds are described in the SAP to guide stopping of each appendix if there is clear evidence of benefit or if there is sufficient evidence to declare futility.

The following schedule and decision thresholds will be followed for IAs:

- i) Screening IA (n=300):
  - a. The study drug is found to have benefit (efficacy). Study drug appendix will proceed to primary objective IA at n=300. *Note: this is also a check for harm as all assessments are two-tailed.*
  - b. The study drug is not found to have benefit, enrollment continues in the study drug appendix and sIA is repeated at n=600.
- ii) Screening IA (n=600):
  - a. It would be futile to attempt to show a benefit of the study drug based on the predicted probability of success (PPOS) and other factors. The study drug appendix will be terminated.
  - b. Futility is not determined. Study drug appendix will proceed to primary objective IA at n=600.
- iii) Primary Objective IA (n=300): if the criteria for proceeding to the primary objective are met when n=300, a primary objective IA will be conducted. The following decisions will be assessed:
  - a. The study drug is found to have benefit (efficacy), the study drug appendix will be terminated as the primary endpoint has been met.

- b. It would be futile to attempt to show a benefit of the study drug within the PPOS and other factors. The study drug appendix will be terminated.
  - c. Efficacy/futility is undeterminable, enrollment will continue in the study drug appendix and the primary objective IA will be assessed at n=600.
- iv) Primary Objective IA (n=600, 900): if the criteria for proceeding to the primary objective IA are met when n=600 or n=900, a primary objective IA will be conducted. The following decisions will be assessed:
  - a. The study drug is found to have benefit (efficacy), the study drug appendix will be terminated as the primary endpoint has been met.
  - b. It would be futile to attempt to show a benefit of the study drug based on the PPOS and other factors. The study drug appendix will be terminated.
  - c. Efficacy/futility is undeterminable, enrollment will continue in the study drug appendix and the primary objective will be assessed after another 300 participants have been enrolled, or until n=900, and then again at n=3000.
- v) Secondary Objective IA (n=600 passing Day 90): A futility analysis on the PASC endpoint will be conducted when 600 participants have passed day 90 under the assumption of accrual to n=3000.

Interim analyses beyond n=900: subsequent to planned interim analyses, the evaluation of continuation of a study arm will consider achieving the primary objective, the secondary objective of preventing PASC, and any external stakeholder evidentiary needs with evaluation according to the schedule of DSMB meetings. The analysis for the sIA will use a covariate adjusted statistical model. The outcome is an ordinal variable, which is the overall symptom burden measured on a none / mild / moderate / severe scale with hospitalization and death added as the 5<sup>th</sup> and 6<sup>th</sup> level of the ordinal scale. The outcome is measured daily for 14 days. The outcome is compared between participants receiving study drug and participants receiving placebo each of the 14 days using a longitudinal statistical model that considers the repeated measurements on each participant. The statistical model can be used to estimate the days of benefit – the number of days for which being on an active study drug results in a better outcome than being on a comparator. Days benefit, restated in terms of concordance and discordance probabilities, is the difference between (a) the probability that the intervention is better and (b) the probability that the non-intervention is better, summed over all the days of follow-up. This is the main quantity, or estimand, that will be used to make early go/no-go decisions for each appendix.

The primary objective IA will follow processes described in Section 10.6.3 for assessment of efficacy. The primary endpoint used for the primary objective IA will be selected per appendix prior to the initial IA.

A posterior probability of meaningful benefit for a study drug in comparison to the placebo control of greater than the specified threshold will result in a declaration of overall superiority. A PPOS when n=3000 is less than the specified threshold will result in a declaration of futility.

Futility is a low probability of achieving any conclusions within a reasonable time frame or within the context of the trial. Prior to each IA, the target date for study completion will be specified, and accrual will be projected by that target date. A statistical model may be used to

predict accrual. Futility assessment will use the lowest of either the planned accrual or predicted accrual at study closure.

The combination of decision thresholds and effect sizes have been selected to balance the ability to observe a meaningful effect on symptoms, to observe the potential for an effect on clinical outcomes, and to maximize power while controlling the Type 1 error rate. For each appendix, decision making thresholds will be set to achieve appendix-specific goals and simulations will be used to demonstrate that the operating characteristics are consistent with a Type I error control of at least 5%, as described in the SAP.

#### **9.6.5. Sensitivity and Supplementary Analyses**

The sensitivity analyses described in the SAP are designed to test robustness of the results to assumptions in the statistical models. In addition to checking assumptions about the modeling approach, association of adherence with outcomes will also be ascertained. In the main statistical model, the number of doses of study drug consumed or weight adjusted dose will be added as a covariate to investigate a possible dose response curve.

#### **9.6.6. Differential Treatment Effects and Subgroup Analyses (Acute Disease)**

Differential treatment effect, also referred to as heterogeneity of treatment effect, refers to differences in treatment efficacy as a function of pre-existing participant characteristics such as baseline variables. This is often assessed by forming subgroups. However, these subgroups do not inherit the baseline covariate adjustment of the full participant outcome model, and are problematic because of improper subgrouping when a continuous variable is used. For example, dichotomizing age at 65 years is arbitrary and it is very unlikely that any study drug effect has a discontinuity in effect at 65 years old. Also, subgroup estimates and statistical assessments of them are unreliable and are often taken out of context when a more systematic analysis does not find evidence for an interaction between the covariate and study drug.

For these reasons, analysis of differential study drug effect will be prespecified and model based. For example, effectiveness variability can be estimated with continuous age by adding a smooth age by study drug interaction into the model and using this model to estimate treatment contrast and their uncertainties across age = 10, 11, ..., 100. Differential treatment effects by sex, body mass index, and age will be examined. Prior to the final analysis, additional important subgrouping variables will be defined and listed in the SAP. Knowledge about concomitant therapies, risk factors, and vaccinations are expected to continue to evolve and inform the final decision on their inclusion in these analyses.

Studies under this master protocol will be sized only for assessing overall study drug effects. Thus, there may be inadequate power to (1) examine interactions and to (2) estimate covariate-specific treatment effects (e.g., odds ratio at age 70 or for females).

#### **9.6.7. Secondary Clinical Endpoint (Acute Disease)**

The COVID Clinical Progression Scale score on Day 14 will be compared between participants in each study drug arm and the placebo arm using a covariate adjusted proportional odds model. A similar approach will be used for QOL and PASC score outcomes. Covariates will be prespecified and will include at a minimum: age, baseline severity, and duration of illness. The

proportional odds assumption will mainly be examined using graphical methods. If proportionality is clearly violated, a partial proportional odds or non-proportional odds models will be considered. As before, a Bayesian approach to model interpretation will be used. For estimating time to symptom resolution based on the definition of at least three consecutive days without symptoms, a proportional hazards model will be used. Since death is a competing risk, cause-specific hazards will be estimated. Observations will be censored at 28 days.

#### **9.6.8. Exploratory Analysis (Acute Disease)**

Exploratory analyses involve the same outcome variables, measured at 90, 120, or 180 days. Exploratory analysis will focus on describing long term outcomes, particularly symptoms and severity, clinical status, and QOL. Statistical models will use a similar form as for the main analysis. As well as simple analysis that consider the effect of treatment on long term outcomes, the SAP will describe how participant state during the intervention period will be used to inform longer term outcomes.

#### **9.6.9. Adherence and Retention Analysis**

Withdrawals from study drug and consent withdrawals will be tracked via the online system. Participants will be asked about their use of study drug. Those reporting discontinuation or switching will be asked about the reasons for discontinuation/switching.

Measures of study retention to inform follow-up time will be based on several measures, including web-based check-ins for symptoms and COVID-19 outcome reporting.

#### **9.7. Interim Reporting**

In addition to routine evaluation of decision thresholds pursuant to the statistical design of this study, regular IDMC reviews will be conducted to ensure the safety of study participants. Regular IDMC meetings will monitor the following parameters at a minimum:

- Recruitment progress
- Enrollment overall and by subgroups
- Adherence, retention, and status of data collection
- Events of special interest (ESIs)
- Unanticipated problems
- Serious adverse events (SAEs)

Interim examination of clinical endpoints will be based on the accrual of primary endpoint data. It is expected that reviews of the data will occur approximately after each 300 participants are enrolled in each study drug appendix (150 in study drug arm and 150 in placebo arm).

For ethical reasons, interim examinations of key safety and process data will be performed at regular intervals during the course of the trial. The DCC will create reports to track participant enrollment, rates of adherence with the assigned treatment strategy, and frequency of protocol violations. Prior to each meeting, the DCC will conduct any requested statistical analyses and prepare a summary report along with the following information: participant enrollment reports, rates of adherence with the assigned treatment, and description of SAEs.

Safety reports will be prepared for the IDMC approximately weekly once enrollment begins. The prespecified stopping thresholds are intended to guide the interpretation of interim analyses and are not a strict rule for early termination. It is expected that both internal and external factors will influence the decisions of the IDMC. The SAP will describe the planned interim analyses and futility monitoring in detail.

#### **9.8. Independent Data Monitoring Committee (IDMC)**

The IDMC will monitor participant safety and study performance. An IDMC charter that outlines the operating guidelines for the committee and the procedures for the interim evaluations of study data will be developed and agreed upon by the IDMC. Reports will be prepared by the DCC in accordance with the plan outlined in the charter, or as requested by the IDMC chair, and will include interim analyses of primary and secondary endpoints, additional safety events, and other information as requested by the committee. After each scheduled closed meeting, the IDMC will send a recommendation to the IND sponsor to continue, modify, or terminate the study. After approval, the recommendations will be forwarded by the clinical coordinating center (CCC) to investigators for submission to their local, regional and national IRB/Ethic Committees, as applicable. Please refer to the IDMC Charter for further details.

#### **9.9. Adjudication Committee**

The medical records will be requested for all participants reporting a hospitalization and/or death at any point during the study. For each participant-reported hospitalization or death event, the DCRI Clinical Event Ascertainment (CEA) group will review the medical records and confirm the occurrence and root cause of the event as part of an adjudication process. The CEA group includes specialists relevant to the hospitalization or death events of interest, additional details about review procedures will be provided in an adjudication charter.

## **10. Ethical Standards**

### **10.1. Institutional Review Board (IRB)**

The protocol, ICF(s), recruitment materials, and all participant materials will be submitted to the IRB(s) of record for review and approval. This approval must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB(s) before being implemented in the study. All changes to the consent form will also be IRB-approved and a determination will be made regarding whether previously consented participants need to be re-consented.

### **10.2. Informed Consent Process**

All consenting will occur either via an electronic consent process or a paper process. Consent forms describing in detail the study drug/placebo, study procedures, and risks will be given to the participant and documentation of informed consent is required prior to starting study procedures. Informed consent is a process that is initiated prior to the individual's agreement to participate in the study and continues throughout the individual's study participation. A description of risks and possible benefits of participation will be provided to the participants. A description of the current available therapies as part of usual care outside of this trial will be provided to the participants and clarification that receipt of such therapies are not part of exclusion criteria will also occur. Consent forms will be IRB-approved and the participant will be asked to read and review the document. The participant will be provided a phone number and email in the event they have questions about study participation. This will allow them to communicate with the investigators (or their delegate), for further explanation of the research study and to answer any questions that may arise, as necessary. Participants will have the opportunity to carefully review the consent form and ask questions prior to signing.

The participants should have the opportunity to discuss the study and think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically for the study. The participants may withdraw consent at any time throughout the course of the study. A copy of the informed consent document will be provided to the participants for their records. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.

The study team will distinguish between the desire to discontinue study drug and the desire to withdraw consent for study follow-up. In the event that a participant withdraws consent, the investigator or his/her designee will clarify with the participant and document whether the withdrawal is temporary or permanent, and if a full or partial withdrawal.

### **10.3. Participant and Data Confidentiality**

Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples in addition to the clinical and private information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized

third party without prior written approval of the sponsor. The study participant's contact information will be securely stored in the clinical study database.

Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the DCC. The study data entry and study management systems used by clinical sites and by research staff will be secured and password protected. At the end of the study, all study-related data storage systems will be archived according to local processes.

#### **10.4. Site Management and Quality Assurance**

The study team will work in tandem to ensure that the data collected in this study are as complete and correct as possible. A four-step, multi-functional approach to quality control will be implemented:

- **Training:** Prior to the start of enrollment, the clinician investigators and key study personnel at each site will be trained with the clinical protocol and data collection procedures, including how to use the Electronic Data Capture (EDC) system. Follow-up training and training for new study personnel or new versions of the protocol will be conducted as needed.
- **Monitoring:** The CCC, along with the DCC, will ensure that data collection is handled properly, will provide in-service training, and will address questions from site investigators and coordinators. Electronic review of data quality and completeness will occur on a regular and ongoing basis. Any issues will be addressed. At a minimum, source document verification will occur, as needed, for confirmation of COVID-19 diagnosis and hospitalization(s).
- **Managing data:** After the data have been transferred for statistical summarization, data description, and data analysis, further crosschecking of the data will be performed with discrepant observations being flagged and appropriately resolved through a data query system.
- **Reviewing data:** Data regarding events of interest will be reviewed to ensure appropriate documents are collected for IDMC review. The DCC will monitor standardized classification of symptoms and contact site study teams when events comprising the primary endpoint are not complete.

#### **10.5. Site Monitoring**

This study will employ a centralized risk-based approach to monitoring with routine and periodic review of participant-submitted data to validate the informed consent process, select eligibility criteria, hospitalization, identify and follow-up on missing data, inconsistent data, data outliers, etc. and ensure completion of administrative and regulatory processes. The study team will facilitate regular communication through training sessions, teleconferences, videoconferencing, email, etc. Using quality-by-design principles, steps will be taken at the study design stage to foresee and limit problems that might occur during the study conduct. Follow-up from the online system and call center is expected to keep participants engaged. Minimal levels of intervention and a focus on observing rather than influencing the study participants greatly increases the likelihood that Good Clinical Practices will be followed. Central statistical monitoring is



particularly useful for identifying unusual patterns in data. An integrated approach to quality surveillance will be deployed, which will be detailed in the appropriate study management plans.

## **11. Data Handling and Record Keeping**

### **11.1. Data Collection and Management Responsibilities**

Minimizing research activities and conducting the trial in a pragmatic manner will increase the ability to complete the trial in the face of strained clinical and research resources during the COVID-19 pandemic. Data will be collected by electronic methods, supplemented by telephone or videophone follow-up and from the electronic health record.

Data will be collected directly from participants using REDCap through text messaging or email with a survey link, or phone call as back up. The process for using text messaging is Health Insurance Portability and Accountability Act (HIPAA) compliant.

Site personnel or participants will enter study data into a secure online database. Data will be maintained in a secure online database until the time of study publication. At the time of publication, the DCC will generate a de-identified version of the database for archiving (see Section 12.4).

### **11.2. Study Records Retention**

Study documents should be retained for a minimum of six years after the study has ended. However, if required by local regulations, these documents should be retained for a longer period. No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.

### **11.3. Protocol Deviations**

A protocol deviation is defined as non-compliance with the clinical study protocol, GCP, or MOP requirements. The non-compliance may be on the part of the participant, site investigator, or the site staff.

A major protocol deviation is a significant divergence from the protocol that may have significant effect on the participant's safety, rights, or welfare and/or on the integrity of the study data. Major protocol deviations must be sent to the study IRB and local IRB per their guidelines, recorded in source documents, and reported to the coordinating center. Major protocol deviations will be tracked. For this study, any missed or delayed survey completion will not be considered a major protocol deviation. Refer to the MOP for details.

### **11.4. Publication and Data Sharing Policy**

This study will comply with the NIH Public Access Policy, which ensures that the public has access to the results of NIH-funded research. Methods of data sharing will include 1) archiving de-identified data in a data repository and 2) sharing of limited datasets under a Data Use Agreement (DUA) and IRB approval. Data will be made available to qualified investigators by archiving a fully de-identified dataset in a platform to be determined at the end of the trial. Both repositories allow users to search, view study information, and then submit an application to receive data. Prior to archiving study data, the DCC will produce a final dataset that will be stripped of all personal health information (PHI) in compliance with the HIPAA privacy rule.

The relative timing of an event will be retained in the dataset converting to study days instead of dates.


The study result will be returned, including some participant specific results, to enhance value from participation. Study results will be disseminated to the public and the medical community through presentations at scientific meetings and publishing manuscripts in high impact peer-reviewed journals. The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical studies registration policy as a condition for publication. The ICMJE defines a clinical study as any research project that prospectively assigns human participants to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. The ICMJE policy, and the Section 801 of the Food and Drug Administration Amendments Act of 2007, requires that all clinical studies be registered in a public registry such as ClinicalTrials.gov, which is sponsored by the National Library of Medicine. For interventional clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee's responsibility to register the study in an acceptable registry, so the research results may be considered for publication in ICMJE member journals.

## 12. Study Leadership

The Steering Committee is a multi-stakeholder committee that oversees the study and includes representatives from clinical sites, the trial coordinating center, the NIH, PCORI, Operation Warp Speed, the FDA, National Center for Advancing Translational Sciences (NCATS), ACTIV representatives with no conflict of interest, and academic and industry advocates.

The CCC and DCC are each overseen by PI(s). The CCC is responsible for study coordination, site management, communication, and financial administration. The DCC is responsible for treatment allocations, receipt and processing of data, quality control programs, and statistical analysis and reporting.

An independent IDMC will oversee the safety and welfare of trial participants as well as provide recommendations for continuation, discontinuation or revision of the trial.



**Figure 3: Operational Structure Diagram**

**13. Summary of Changes**

Protocol Version (version #, date)	Summary of Changes
Version 1.0, 01APR2021	N/A, Version 1.0
Version 2.0, 25MAY2021	<ul style="list-style-type: none"> <li>• Added current use of study drug or study drug/device combination as an exclusion criterion (Sections 1.1 and 5.2);</li> <li>• Added a phone call follow-up the day after first study drug dose, clarified that follow-up will occur if two consecutive days of reporting are missed during Days 3-14, and added that sites/call center will collect missing survey information during follow-up calls (Section 7.3);</li> <li>• Added at-home pulse oximetry readings and description of at-home pulse oximetry reading collection (Table 1 and Section 8.2);</li> <li>• Added symptom severity scale (Section 8.2);</li> <li>• Added Adverse Device Effect and Unanticipated Adverse Device Effects definitions, collection/reporting period details, and causality assessment details (Sections 9.1.1, 9.1.2, 9.1.3, 9.1.4);</li> <li>• Clarified that hypoxia ESI will only be collected from hospitalized participants (Section 9.1.5);</li> <li>• Clarified that any missing or delayed survey completion will not be considered a major protocol deviation (Section 12.3);</li> <li>• Updated Ivermectin and matched placebo information and packaging (Sections 16.3, 16.3.1, 16.3.3, 16.4.1);</li> <li>• Added Appendix B – Fluvoxamine maleate (Section 17);</li> <li>• Added Appendix C – Fluticasone Furoate (Section 18);</li> <li>• Changed symptom freedom to symptom resolution for consistency throughout;</li> <li>• Other administrative changes throughout.</li> </ul>

Version 3.0, 06JUL2021	<ul style="list-style-type: none"> <li>• Clarified that the sample size increase will include 1:1 active study drug to placebo (Section 1.1);</li> <li>• Added footnote 6 to COVID-19 Outcomes during Intervention Period to clarify that these will be assessed on Day 7 and 14 (Table 1);</li> <li>• Added that events that are COVID-19 related AND study drug related and unexpected will be considered reportable (Section 9.1.4);</li> <li>• Updates made to fluvoxamine appendix: excluded linezolid, use of fluoxetine within 45 days of consent, and bipolar disorder per FDA feedback (Section 17.2); added precautions of additional drugs including tramadol, buspirone, fentanyl, lithium, amphetamines, St. John's Wart, carbamazepine, quinidine, and tacrine per FDA feedback (Section 17.2.1);</li> <li>• Updates made to fluticasone furoate appendix: brand name Arnuity Ellipta replaced with fluticasone furoate throughout (Section 18); changed liver failure exclusion criteria to "moderate to severe hepatic impairment, defined as Child-Pugh B or C" (Section 18.2); removed hepatic impairment precautions as it was added to exclusion criteria (Section 18.2.1);</li> <li>• Other minor administrative changes throughout.</li> </ul>
Version 4.0, 20DEC2021	<ul style="list-style-type: none"> <li>• Removed protocol number as no protocol number will be assigned;</li> <li>• Changed primary objective from symptom reduction to effectiveness based on clinical outcome endpoints of hospitalization/death or time to recovery (Sections 1.1 and 3);</li> </ul>

	<ul style="list-style-type: none"> <li>• Removed unnecessary “e.g., hospitalization and death” from first secondary objective (Sections 1.1 and 3);</li> <li>• Added rationale for sIA (Sections 1.1 and 4);</li> <li>• Inclusion criterion #3: added reinfection (Sections 1.1 and 5.1);</li> <li>• Exclusion criteria updates: Removed “prior diagnosis of COVID-19 infection (&gt;10 days from screening)” as it was causing confusion for sites and is already covered by Inclusion criterion #3; specified that current or recent hospitalization for COVID-19 infection is exclusionary, not all hospitalizations; added a time window for current or recent use of study drug or combination for within the last 14 days; added “current or planned participation in another interventional trial to treat COVID-19, at the discretion of the study PI” (Sections 1.1 and 5.2);</li> <li>• Sample size considerations updated to include sIA (Sections 1.1 and 10.2);</li> <li>• Statistical considerations for Primary Analysis updated to align with change in primary objective and IAs (Sections 1.1, 10.6.1, and 10.6.3);</li> <li>• Interim Analysis updated to specify that IA will occur ~ every 300 participants instead of every 200, included sIA, and primary objective IA (Sections 1.1, 10.6.4, and 10.7);</li> <li>• Added <b>Figure 2</b> to portray IA process (Section 1.2);</li> <li>• Updated study background and rationale based on new data (Sections 2.1 and 2.2);</li> <li>• Updated secondary outcome measures and reported endpoints (Section 3);</li> <li>• Added additional information regarding arm eligibility depending on the number</li> </ul>
--	--

	<p>of arms open to provide clarity for sites (Section 4.1);</p> <ul style="list-style-type: none"> <li>• Added that screen failures also include participants who consent, then on review by the site, are found to be ineligible for the study (Section 5.4);</li> <li>• Added additional reasons why participant may not receive study drug/placebo and specified that these participants would be identified as randomized not enrolled, instead of consented not enrolled (Section 5.5);</li> <li>• Specified that participants will be contacted directly if the miss one daily symptom reporting during Days 3 to 14 (Sections 7.3 and 9.1.2);</li> <li>• Clarified that all participants will be asked to complete symptom reporting on Days 21 and 28, regardless of symptom resolution (Table 1, Section 8.1.3);</li> <li>• Added that “overall symptom burden” is collected as part of Symptom Reporting (Section 8.2);</li> <li>• Updated primary hypothesis to align with updated primary objective (Section 10.1.1);</li> <li>• Model priors section removed and Statistical modeling simplified to refer to detailed description in SAP as models will be adjusted per appendix (Section 10.6.2);</li> <li>• Removed details of sensitivity analysis and referred to SAP (Section 10.6.5);</li> <li>• Clarified that additional subgrouping variables may be added to the SAP prior to final analysis (Section 10.6.6);</li> <li>• Changed Appendix A – Ivermectin title to Ivermectin 400 (Section 16); removed CYP3A4 and P-gp precautions as not noted in the IB for the ivermectin study drug (Section 16.2.1); in Section 16.2, deleted “use of warfarin, CYP3A4, P-gp inhibitor drugs, or CYP3A4 substrates”</li> </ul>
--	---



	<p>appendix-level exclusion criteria and added “Current or planned use of the following drugs:</p> <ul style="list-style-type: none"> <li>○ Antiarrhythmic/antihypertensive drug class: quinidine, amiodarone, diltiazem, spironolactone, verapamil</li> <li>○ Antibiotic-macrolides drug class: clarithromycin, erythromycin</li> <li>○ Antifungal drug class: itraconazole, ketoconazole</li> <li>○ Immunosuppressant drug class: cyclosporine, tacrolimus</li> <li>○ Anti-HIV drug class: indinavir, ritonavir”;</li> <li>• Added Appendix D – Ivermectin 600 (Section 19);</li> <li>• Other administrative changes throughout.</li> </ul>
Version 5.0, 17MAR2022	<ul style="list-style-type: none"> <li>• Added illness severity objective (Sections 1.1 and 3);</li> <li>• Removed reference to appendix-specific SAP, only significant deviations from the main SAP analysis will require appendix-specific SAPs. Choice of primary objective, covariates, etc. will be documented outside of the SAP (Sections 1.1, 10.2, 10.6, 10.6.3, 10.6.4);</li> <li>• Clarified that primary objective occurs at 28 days (Sections 1.1 and 3);</li> <li>• Updated COVID-19 status, vaccination, and treatment options background (Sections 1.1 and 2.1);</li> <li>• Defined “receipt of study drug” (Section 5.5);</li> <li>• COVID-19 vaccination added to abbreviated medical history (Section 8.2);</li> <li>• Updated instructions for unblinding (Section 10.4);</li> <li>• Specified that covariates will take into account emerging data and changing context (Section 10.6.2);</li> </ul>

	<ul style="list-style-type: none"> <li>• Added that this study operates in addition to usual care in additional protocol locations (Sections 11.2 and 2.1);</li> <li>• Appendix A closed to enrollment on 04FEB2022;</li> <li>• Appendix C closed to enrollment on 08FEB2022;</li> <li>• Added Appendix E – Combination Fluvoxamine Maleate and Fluticasone Furoate;</li> <li>• Added Appendix F – Montelukast (Section 21);</li> <li>• Other administrative changes throughout.</li> </ul>
Version 6.0, 17JUN2022	<ul style="list-style-type: none"> <li>• Appendix B closed to enrollment on 27FEB2022;</li> <li>• Removed appendix for combination fluvoxamine maleate and fluticasone furoate arm;</li> <li>• Added Appendix E – Fluvoxamine Maleate 100;</li> <li>• Added neuropsychiatric events of special interest in Montelukast appendix;</li> <li>• Updated the final visit from 90 to 120 days, effective only for arms Fluvoxamine Maleate 100 and Montelukast (footnotes added throughout for Day 120);</li> <li>• Other administrative changes throughout.</li> </ul>
Version 7.0, 08DEC2022	<ul style="list-style-type: none"> <li>• Added C-SSRS collection to the Fluvoxamine Maleate 100 Appendix on Day 7 and Day 14 and included in the Schedule of Events (Section 8.1.2, 20.5, and Table 1);</li> <li>• Changed the Final Visit to Day 180 for participants consented to protocol v7.0 (Section 3, 5.3.2, 8.1.3, 8.1.4, 9.1.2, 10.6.8, and Table 1);</li> <li>• Added PASC Symptom Questionnaire (Section 8.1.4, 8.2, and Table 1);</li> <li>• Added C-SSRS and PASC as abbreviations;</li> <li>• Other administrative changes throughout.</li> </ul>

Version 8.0, 19APR2023	<ul style="list-style-type: none"> <li>• Updated maximum participation duration to align with changes made in the previous amendment (Section 1.1);</li> <li>• Added exclusion of previous or current enrollment in the ACTIV-6 trial (Sections 1.1 and 5.2);</li> <li>• Updated specifics of study endpoints (Section 3);</li> <li>• Clarified statistical details (Section 10) and added the number of events required to perform inference (Section 10.6.2);</li> <li>• Added closure date of Appendix E – Fluvoxamine Maleate 100 (Section 20);</li> <li>• Clarified that the C-SSRS will only be done on participants enrolled in the fluvoxamine maleate 100 arm on protocol v7.0 or higher (Section 20.5);</li> <li>• Excluded ACTIV-6 study team members from enrollment on the montelukast appendix (Section 21.2);</li> <li>• Added details of the additional montelukast study drug provider and removed debossing details from the montelukast tablet description (Sections 21.3.1, 21.3.2, and 21.4.1);</li> <li>• Added Appendix G – Metformin Hydrochloride Immediate-Release (Section 22);</li> <li>• Other administrative changes throughout.</li> </ul>
Version 9.0, 16JUL2023	<ul style="list-style-type: none"> <li>• Expanded screening window to 7 days due to operational challenges with shipping drug within 2 days (Section 8.1);</li> <li>• Added hypoglycemia reporting at Day 14 for Appendix G only (Section 8.1 and 8.1.2);</li> <li>• Added enrollment closure dates for Appendix D and F;</li> <li>• Updated exclusion criteria for Appendix G based on FDA feedback (Section 22.2);</li> <li>• Added lactic acidosis and hypoglycemia as ESIs to Appendix G based on FDA feedback (Section 22.5);</li> </ul>

	<ul style="list-style-type: none"><li>• Other administrative changes throughout.</li></ul>
Version 10.0, 02AUG2023	<ul style="list-style-type: none"><li>• Updated exclusion criteria for Appendix G based on FDA feedback (Section 22.2).</li></ul>
Version 11.0, 26DEC2023	<ul style="list-style-type: none"><li>• Added secondary objective (Section 3, synopsis)</li><li>• Adjusted main analysis sample size to 3000 (Section 10.6)</li><li>• Clarified between the analyses for acute COVID and PASC (Sections 10.6.4, 22.6)</li></ul>
Version 12.0, 05JUN2024	<ul style="list-style-type: none"><li>• Added Post-acute disease objectives and endpoints (Section 3) that are specific to Appendix G, with corresponding statistical language to the main protocol (Section 9) and the metformin appendix (Section 21.7)</li></ul>

## 14. References

1. *COVID-19 Map FAQ*. 2020 [cited 2020; Available from: <https://coronavirus.jhu.edu/map-faq.html>].
2. McIntosh, K. *Coronavirus disease 2019*. 2020 [cited 2020 March 24].
3. Beigel, J.H., et al., *Remdesivir for the Treatment of Covid-19 — Final Report*. New England Journal of Medicine, 2020. **383**(19): p. 1813-1826.
4. *Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report*. New England Journal of Medicine, 2020.
5. Gordon, A.C., et al., *Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report*. medRxiv, 2021: p. 2021.01.07.21249390.
6. Baden, L.R., et al., *Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine*. New England Journal of Medicine, 2020. **384**(5): p. 403-416.
7. Polack, F.P., et al., *Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine*. New England Journal of Medicine, 2020. **383**(27): p. 2603-2615.
8. Voysey, M., et al., *Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK*. The Lancet, 2021. **397**(10269): p. 99-111.
9. Wang, Z., et al., *mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants*. bioRxiv, 2021: p. 2021.01.15.426911.
10. Grein, J., et al., *Compassionate Use of Remdesivir for Patients with Severe Covid-19*. New England Journal of Medicine, 2020. **382**(24): p. 2327-2336.
11. Beigel, J.H., et al., *Remdesivir for the Treatment of Covid-19 — Preliminary Report*. New England Journal of Medicine, 2020.
12. Wyatt, M.A., et al., *Implementation of the “Pregnancy Reasonably Excluded Guide” for Pregnancy Assessment: A Quality Initiative in Outpatient Gynecologic Surgery*. Obstetrics & Gynecology, 2018. **132**(5): p. 1222-1228.
13. Print, W.H.O.R.D.B. *Novel Coronavirus COVID-19 Therapeutic Trial Synopsis*. 2020.
14. Cabrera Martimbianco, A.L., et al., *Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review*. Int J Clin Pract, 2021. **75**(10): p. e14357.
15. Huang, C., et al., *6-month consequences of COVID-19 in patients discharged from hospital: a cohort study*. The Lancet, 2021. **397**(10270): p. 220-232.
16. Hirschtick, J.L., et al., *Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics*. Clin Infect Dis, 2021. **73**(11): p. 2055-2064.
17. Bell, M.L., et al., *Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT*. PLOS ONE, 2021. **16**(8): p. e0254347.
18. Davis, H.E., et al., *Characterizing long COVID in an international cohort: 7 months of symptoms and their impact*. eClinicalMedicine, 2021. **38**.

19. Cella, D., et al., *The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years*. Med Care, 2007. **45**(5 Suppl 1): p. S3-S11.
20. Hays, R.D., et al., *PROMIS(®)-29 v2.0 profile physical and mental health summary scores*. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2018. **27**(7): p. 1885-1891.
21. Whitehead, J., *Sample size calculations for ordered categorical data*. Stat Med, 1993. **12**(24): p. 2257-71.
22. Boussinesq, M., et al., *Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon*. Filaria journal, 2003. **2 Suppl 1**(Suppl 1): p. S4-S4.
23. Makenga Bof, J.C., et al., *Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post-war environment*. Trop Med Int Health, 2015. **20**(1): p. 48-62.
24. Chandler, R.E., *Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?* Am J Trop Med Hyg, 2018. **98**(2): p. 382-388.
25. Barkwell, R. and S. Shields, *Deaths associated with ivermectin treatment of scabies*. Lancet, 1997. **349**(9059): p. 1144-5.
26. MERCK & CO., I. *TABLETS STROMECTOL (R) (IVERMECTIN) Product Label*. 2009 [cited 2021 February 12]; Available from: file:///U:/Personal/My%20Documents/Medical%20Writing/COVID/ACTIV-6/Study%20Drugs/Ivermectin.pdf.
27. Nicolas, P., et al., *Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis*. The Lancet Global Health, 2020. **8**(1): p. e92-e100.
28. Pacqué, M., et al., *Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution*. The Lancet, 1990. **336**(8729): p. 1486-1489.
29. Addiss, D.G., et al., *Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for *Wuchereria bancrofti* microfilaraemia in Haitian children*. The Lancet, 1997. **350**(9076): p. 480-484.
30. Dreyer, G., et al., *Treatment of bancroftian filariasis in Recife, Brazil: a two-year comparative study of the efficacy of single treatments with ivermectin or diethylcarbamazine*. Trans R Soc Trop Med Hyg, 1995. **89**(1): p. 98-102.
31. Heukelbach, J., S. Franck, and H. Feldmeier, *Therapy of tungiasis: a double-blinded randomized controlled trial with oral ivermectin*. Mem Inst Oswaldo Cruz, 2004. **99**(8): p. 873-6.
32. Martin-Prevel, Y., et al., *Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis*. Am J Trop Med Hyg, 1993. **48**(2): p. 186-92.
33. Smit, M.R., et al., *Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated*

- malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.* Lancet Infect Dis, 2018. **18**(6): p. 615-626.
34. LLC, E.P., *Ivermectin Tablets USP, 7mg, 14mg Investigator's Brochure.* 2021.
  35. Yang, S.N.Y., et al., *The broad spectrum antiviral ivermectin targets the host nuclear transport importin  $\alpha/\beta 1$  heterodimer.* Antiviral Res, 2020. **177**: p. 104760.
  36. Caly, L., et al., *The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.* Antiviral Research, 2020. **178**: p. 104787.
  37. Lehrer, S. and P.H. Rheinstein, *Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2.* In Vivo, 2020. **34**(5): p. 3023-3026.
  38. Guzzo, C.A., et al., *Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.* Journal of clinical pharmacology, 2002. **42**(10): p. 1122-1133.
  39. Chaccour, C., et al., *Ivermectin and COVID-19: Keeping Rigor in Times of Urgency.* Am J Trop Med Hyg, 2020. **102**(6): p. 1156-1157.
  40. Arshad, U., et al., *Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.* Clin Pharmacol Ther, 2020. **108**(4): p. 775-790.
  41. Bray, M., et al., *Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.* Antiviral research, 2020. **178**: p. 104805-104805.
  42. Zhang, X., et al., *Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice.* Inflamm Res, 2008. **57**(11): p. 524-9.
  43. Ci, X., et al., *Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway.* Fundam Clin Pharmacol, 2009. **23**(4): p. 449-55.
  44. DiNicolantonio, J.J., J. Barroso-Arranda, and M. McCarty, *Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.* Open Heart, 2020. **7**(2): p. e001350.
  45. Ahmed, S., et al., *A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.* Int J Infect Dis, 2021. **103**: p. 214-216.
  46. Chachar, A.Z.K., et al., *Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients.* International Journal of Sciences, 2021.
  47. Abu Taiub Mohammed Mohiuddin, C., et al., *A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.* Research Square, 2021.
  48. Soto-Becerra, P., et al., *Real-World Effectiveness of Hydroxychloroquine, Azithromycin, and Ivermectin Among Hospitalized COVID-19 Patients: Results of a Target Trial Emulation Using Observational Data from a Nationwide Healthcare System in Peru.* SSRN Electronic Journal, 2020.

49. Hashim, H.A., et al., *Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq*. medRxiv, 2020: p. 2020.10.26.20219345.
50. Khan, M.S.I., et al., *Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19*. Arch Bronconeumol, 2020. **56**(12): p. 828-830.
51. Morgenstern, J., et al., *The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020*. medRxiv, 2020: p. 2020.10.29.20222505.
52. Krolewiecki, A., et al., *Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial*. 2020, SSRN.
53. Podder, C.S., et al., *Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study*. IMC Journal of Medical Science, 2020. **14**(2).
54. Ravikirti, et al., *Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial*. medRxiv, 2021: p. 2021.01.05.21249310.
55. Morteza Shakhshi, N., et al., Research Square, 2021.
56. Espitia-Hernandez, G., et al., *Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study*. Biomedical Research, 2020.
57. Babalola, O., et al., *Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos*. medRxiv, 2021: p. 2021.01.05.21249131.
58. NIH. *COVID-19 Treatment Guidelines Fluvoxamine*. 2021 [cited 2021 April 23]; Available from: <https://www.covid19treatmentguidelines.nih.gov/immunomodulators/fluvoxamine/>.
59. Apotex, *Highlights of Fluvoxamine Maleate Tablets Prescribing Information*.
60. Lenze, E.J., et al., *Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial*. JAMA, 2020. **324**(22): p. 2292-2300.
61. Rosen, D.A., et al., *Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis*. Science Translational Medicine, 2019. **11**(478): p. eaau5266.
62. Rafiee, L., V. Hajhashemi, and S.H. Javanmard, *Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat*. Iran J Basic Med Sci, 2016. **19**(9): p. 977-984.
63. Seftel, D. and D.R. Boulware, *Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19*. Open Forum Infectious Diseases, 2021. **8**(2).



64. GlaxoSmithKline, *Highlights of Prescribing Information for Arnuity Ellipta*. 2018: Online.
65. Yamaya, M., et al., *Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells*. *Respir Investig*, 2020. **58**(3): p. 155-168.
66. Peters, M.C., et al., *COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids*. *Am J Respir Crit Care Med*, 2020. **202**(1): p. 83-90.
67. Finney, L.J., et al., *Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon*. *J Allergy Clin Immunol*, 2021. **147**(2): p. 510-519.e5.
68. Kern, C., et al., *Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing*. *Front Pharmacol*, 2021. **12**: p. 625678.
69. Krolewiecki, A., et al., *Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial*. *EClinicalMedicine*, 2021. **37**.
70. Navarro, M., et al., *Safety of high-dose ivermectin: a systematic review and meta-analysis*. *J Antimicrob Chemother*, 2020. **75**(4): p. 827-834.
71. Smit, M.R., et al., *Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial*. *The Lancet Infectious Diseases*, 2018. **18**(6): p. 615-626.
72. Reis, G., et al., *Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial*. *The Lancet Global Health*, 2022. **10**(1): p. e42-e51.
73. Barré, J., J.-M. Sabatier, and C. Annweiler, *Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence*. *Frontiers in Pharmacology*, 2020. **11**(1344).
74. Copertino, D.C., et al., *Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)*. *J Med Virol*, 2021. **93**(1): p. 187-189.
75. Sanghai, N. and G.K. Tranmer, *Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms*. *Drug Discov Today*, 2020. **25**(12): p. 2076-2079.
76. Al-Kuraishy, H.M., et al., *Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity*. *Eur J Pharmacol*, 2021. **904**: p. 174196.
77. Mao, L., et al., *Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China*. *JAMA Neurology*, 2020. **77**(6): p. 683-690.
78. Marschallinger, J., et al., *Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug*. *Nat Commun*, 2015. **6**: p. 8466.

79. Khan, A.R., et al., *Montelukast in hospitalized patients diagnosed with COVID-19*. The Journal of asthma : official journal of the Association for the Care of Asthma, 2021: p. 1-7.
80. Kerget, B., et al., *Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19*. J Med Virol, 2022. **94**(5): p. 1950-1958.
81. Inzucchi, S.E., et al., *Metformin in patients with type 2 diabetes and kidney disease: a systematic review*. Jama, 2014. **312**(24): p. 2668-75.
82. Salpeter, S.R., et al., *Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus*. Cochrane Database Syst Rev, 2010. **2010**(4): p. Cd002967.
83. Eurich, D.T., et al., *Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients*. Circ Heart Fail, 2013. **6**(3): p. 395-402.
84. Ponikowski, P., et al., *2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC*. Eur Heart J, 2016. **37**(27): p. 2129-2200.
85. Chang, L.L., G.E. Umpierrez, and S.E. Inzucchi, *Management of Hyperglycemia in Hospitalized, Non-Critically Ill Adults*. N Engl J Med, 2022. **387**(11): p. 1040-1042.
86. Haltmeier, T., et al., *Insulin-Treated Patients with Diabetes Mellitus Undergoing Emergency Abdominal Surgery Have Worse Outcomes than Patients Treated with Oral Agents*. World J Surg, 2016. **40**(7): p. 1575-82.
87. Pasquel, F.J. and G.E. Umpierrez, *Web Exclusive. Annals for Hospitalists Inpatient Notes - How We Treat Hyperglycemia in the Hospital*. Ann Intern Med, 2021. **174**(8): p. Ho2-ho4.
88. Reitz, K.M., et al., *Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes*. JAMA Surg, 2020. **155**(6): p. e200416.
89. Brand, K.M.G., et al., *Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study*. BMJ Open Diabetes Res Care, 2022. **10**(1).
90. Hosey, C.M., K. Halpin, and Y. Yan, *Considering metformin as a second-line treatment for children and adolescents with prediabetes*. Journal of Pediatric Endocrinology and Metabolism, 2022. **35**(6): p. 727-732.
91. Hyer, S., J. Balani, and H. Shehata, *Metformin in Pregnancy: Mechanisms and Clinical Applications*. Int J Mol Sci, 2018. **19**(7).
92. Kalafat, E., et al., *Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials*. Ultrasound Obstet Gynecol, 2018. **52**(6): p. 706-714.
93. Masarwa, R., et al., *Efficacy and Safety of Metformin for Obesity: A Systematic Review*. Pediatrics, 2021. **147**(3).

94. Warnakulasuriya, L.S., et al., *Metformin in the Management of Childhood Obesity: A Randomized Control Trial*. Child Obes, 2018. **14**(8): p. 553-565.
95. Prevention, C.f.D.C.a. *Alcohol and Public Health* 2022 April 19, 2022 [cited 2022 August 25]; Available from:  
<https://www.cdc.gov/alcohol/faqs.htm#:~:text=What%20does%20moderate%20drinking%20mean,women%2C%20when%20alcohol%20is%20consumed>.
96. Chen, X., et al., *Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury*. Front Immunol, 2020. **11**: p. 2056.
97. Ventura-López, C., et al., *Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial*. Biomed Pharmacother, 2022. **152**: p. 113223.
98. Buse, J.B., et al., *The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies*. Diabetes Care, 2016. **39**(2): p. 198-205.
99. Henry, R.R., et al., *Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes*. PLoS One, 2018. **13**(9): p. e0203946.
100. Bramante, C.T., et al., *Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19*. New England Journal of Medicine, 2022. **387**(7): p. 599-610.

## 15. Appendix A (Enrollment Closed 04FEB2022) – Ivermectin 400

### 15.1. Risk Assessment

The most commonly reported adverse events for ivermectin are pruritus (25.3%), headache (13.9%), and dizziness (7.5%) (ICH working group, 2003). Since the 1980s, the use of ivermectin in humans for the treatment of filariasis, especially onchocerciasis, has been associated with SAEs, including coma, seizure and death only when administered in regions where *onchocerciasis* and *loiasis* are co-endemic.[22]

The issue of SAEs due to ivermectin is a threat to adherence to mass drug administration and the control and elimination of disease in communities co-endemic with *O. volvulus* and *Loa*. Mass drug administration were suspended from 2004 to 2006 in some health zones in the Equateur, Bas Congo, and Oriental provinces in the Democratic Republic of the Congo because of ivermectin-associated SAEs in the Bas Congo and Oriental provinces in 2003.[23] It has been thought that co-infection with *L. loa* is a risk factor for the development of these reactions.[24] Additionally, a study investigating escalating high doses of ivermectin in healthy adults was performed to explore the safety of its use in the treatment of head lice. The authors documented no evidence of Central Nervous System (CNS) toxicity in doses up to 10 times the highest FDA-approved dose of 200 µg/kg.[25]

**Table 3** shows safety events that occurred in greater than 5% of the clinical trial population who received  $\geq 300$  µg/kg of ivermectin.[26] For a detailed list of the adverse reactions that occurred during clinical trials with ivermectin, refer to the product label and the Investigator's Brochure.

Ivermectin is pregnancy category C and is not contraindicated per FDA. Analyses of outcomes of pregnancies in women inadvertently exposed to ivermectin through mass administration campaigns show no evidence of increased birth defects, neonatal deaths, maternal morbidity, preterm births, or low birthweight over baseline rates.[27, 28]

**Table 3: Ivermectin Adverse Event Table for Doses  $\geq 300$  µg/kg**

Indication (dose)	<i>Wuchereria bancrofti</i> (200-400 µg/kg) [29]	<i>Wuchereria bancrofti</i> (200 µg/kg, then 400 µg/kg on day 4) [30]	Stage II or III <i>tungiasis</i> lesions (300 µg/kg, days 1 & 2) [31]	<i>Loa loa</i> infection (300 or 400 µg/kg) [32]	Symptomatic <i>Plasmodium falciparum</i> malaria (600 µg/kg) [33]
Adverse Reactions					
Abdominal Pain			7%		
Cough	42%				
Diarrhea				6.5%	
Eye disorders					9%

Fever	69%	46%		8%	
Gastrointestinal		18%			
Headache	75%		11%	16%	
Local Inflammation		9%			
Local Pain		9%			
Lumber myalgia				6.5%	
Malaise		27%			
Myalgia	37%				
Neurological		15%			
Pneumonia					9%
Pruritus				60%	
Renal		33%			
Respiratory		33%			

## 15.2. Additional Appendix-Level Exclusion Criteria

1. End-stage renal disease on renal replacement therapy
2. Liver failure or decompensated cirrhosis
3. Current or planned use of the following drugs during the study, listed by drug class:
  - a. Antiarrhythmic/antihypertensive drug class: quinidine, amiodarone, diltiazem, spironolactone, verapamil
  - b. Antibiotic-macrolides drug class: clarithromycin, erythromycin
  - c. Antifungal drug class: itraconazole, ketoconazole
  - d. Immunosuppressant drug class: cyclosporine, tacrolimus
  - e. Anti-HIV drug class: indinavir, ritonavir
4. Nursing mothers
5. Pregnancy\*

*\*Participants must agree to use an effective method of contraception during study drug administration and for at least 3 days after their final dose of study drug. Effective methods include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.*

### 15.2.1. Precautions

While rare, post-marketing reports indicate an increased International Normalized Ratio (INR) when ivermectin was co-administered with warfarin. With a 3-day dosing period this is unlikely

to be a significant issue, but INR monitoring can be recommended to the care provider if felt warranted by site investigator.

### 15.3. Ivermectin Information

Ivermectin is a semisynthetic oral agent used primarily as an anti-parasitic agent. It is derived from highly active, broad-spectrum, anti-parasitic agents isolated from *Streptomyces avermitilis* fermentation products. It binds selectively, and with high affinity, to glutamate-gated chloride ion channels, therefore increasing cell membrane permeability to chloride ions resulting in death of the parasite.[34] It is currently FDA-approved for the following indications: strongyloidiasis of the intestinal tract due to the nematode parasite *Strongyloides stercoralis* and onchocerciasis due to the nematode parasite *Onchocerca volvulus*. [26] Per the FDA-approved labelling of ivermectin, the recommended dose is 200 µg/kg/day to treat strongyloidiasis and 150 µg/kg/day to treat onchocerciasis in the form of a 3 mg tablet.

#### 15.3.1. Formulation, Appearance, Packaging, and Labeling

Ivermectin is a white to yellowish-white, nonhygroscopic, crystalline powder. For this study, ivermectin will be supplied as fifteen 7-mg tablets in a bottle with a single panel label. The tablets are white, round, biconvex tablets with “123” over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.

#### 15.3.2. Drug Dispensing, Storage, and Stability

Ivermectin will be supplied as 7-mg tablets and must be stored at temperatures below 30°C.

#### 15.3.3. Dosing and Administration

Ivermectin should be taken on an empty stomach with water (30 minutes before a meal or 2 hours after a meal). Each participant will receive a bottle of fifteen 7-mg tablets and will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight (see [Table 4](#)) for a daily dose of approximately 300-400 µg/kg.

**Table 4: Ivermectin 400 Dosing Schedule**

Weight (kg)	Day 1 (# of 7-mg tablets)	Day 2 (# of 7-mg tablets)	Day 3 (# of 7-mg tablets)	Daily Dose (µg/kg)
35-52	2	2	2	269-400
53-69	3	3	3	304-396
70-89	4	4	4	315-400
> 90	5	5	5	≤ 389

#### 15.3.4. Rationale for Selection of Dose

##### *Pre-clinical studies:*

Reports from *in vitro* studies suggest that ivermectin acts against ribonucleic acid (RNA) viruses such as SARS-CoV-2 by inhibiting the host importin  $\alpha/\beta$ -mediated nuclear transport that prevent

viral proteins from entering the nucleus to alter host cell function.[35] A single dose addition of ivermectin to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 was able to effect a 5000-fold reduction in viral RNA at 48 hours and may interfere with the attachment of SARS-CoV-2 spike protein to the human cell membrane.[36, 37]

Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell culture. However, pharmacokinetic and pharmacodynamic studies suggest that ivermectin doses up to 100-fold higher than those approved for use in humans would be required to achieve the plasma concentrations necessary to duplicate the drug's antiviral efficacy *in vitro*. [38, 39] Even though ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, predicted systemic plasma and lung tissue concentrations are much lower than 2  $\mu$ M, the half-maximal inhibitory concentration (IC<sub>50</sub>) against SARS-CoV-2 *in vitro*. [40, 41]

Ivermectin demonstrates potential anti-inflammatory properties in some *in vitro* studies, properties which have been postulated to be beneficial in the treatment of COVID-19. [42-44] The dose range for an anti-inflammatory effect may be lower than for the anti-viral effects. [44]

### ***Clinical studies:***

A number of retrospective cohort studies and the results of several randomized trials of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as preliminary, non-peer-reviewed reports. Some clinical studies showed no benefits after ivermectin use, whereas others reported shorter time to resolution of disease manifestations attributed to COVID-19, greater reduction in inflammatory markers, shorter time to viral clearance, or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo. [45-50]

Most of the studies reported to date are limited by their small sample size, varying dosing schedules and the adjunctive use of various concomitant medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true efficacy or safety of ivermectin. Clinical studies in outpatients with COVID-19 did not always describe the severity of COVID-19 and the study outcome measures were not always defined. Nonetheless, while some have shown no difference, most clinical trials of outpatients with mild/moderate COVID-19 have shown clinical improvement with even a single dose or a short two to five-day course of ivermectin given orally shortly after symptom onset. [39, 49, 51, 52]

There is a dose-dependent relationship between ivermectin dose and clinical efficacy. Trials using lower doses of ivermectin tend to show no or minimal clinical benefit in COVID-19 patients treated in the outpatient or hospital setting. [53, 54] Higher doses, at least 0.4 mg/kg, particularly when administered in multiple doses, have been shown to significantly reduce time to recovery and mortality as compared with lower doses or placebo/standard care. [51, 55-57] There is a concentration-dependent virologic response seen using higher-than-usual doses of ivermectin (600  $\mu$ g/kg vs 200  $\mu$ g/kg once daily for 5 days) that have been shown to significantly reduce the time to PCR viral positivity over standard doses with minimal associated toxicities. [52]

The safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin was tested in healthy adult subjects. [38] Doses from 30 mg/day (**347-571  $\mu$ g/kg**) to 120 mg/day (**1404-2000**

µg/kg) given for 3 days were all well tolerated.[38] These data coupled with evidence of superior clinical efficacy of doses in the lower of this range provide the rationale for the 300-400 µg/kg dose given for 3 days in the proposed trial.

#### **15.4. Placebo Information**

##### **15.4.1. Formulation, Appearance, Packaging, and Labeling**

Placebo will match the appearance of the 7-mg ivermectin tablets: white, round, biconvex tablets with “123” over the scoring on one side. A total of fifteen tablets will be provided in a bottle with a single panel label. The placebo formulation includes the following ingredients in a 210 mg tablet: microcrystalline cellulose, NF (MC-102; pregelatinized starch, NF (Starch 1500); croscarmellose sodium, NF (Vivasol, GF Grade); colloidal silicon dioxide, NF (Aerosil 200) and magnesium stearate, NF (2257). All packaging will be labeled to indicate that the product is for investigational use.

##### **15.4.2. Drug Dispensing, Storage, and Stability**

Placebo must be stored at temperatures below 30°C.

##### **15.4.3. Dosing and Administration**

Dosing and administration will occur according to Section [16.3.3](#) in order to maintain blinding.

#### **15.5. Events of Special Interest**

None



## 16. Appendix B (Enrollment Closed 27MAY2022) – Fluvoxamine Maleate

### 16.1. Risk Assessment

The most common adverse effects of fluvoxamine described in the setting of treatment of psychiatric conditions include gastrointestinal effects, neurological effects, dermatological reactions, and in rare cases suicidal ideation.[58] In two 10-week controlled trials in Obsessive Compulsive Disorder (OCD) and depression at doses ranging from 100-300 mg/day, the most commonly observed adverse reactions associated with the use of fluvoxamine maleate tablets (incidence of 5% or greater and at least twice that for placebo) were nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, and vomiting (see [Table 5](#)).[59]

[Table 6](#) lists the complete set of adverse events identified in a randomized clinical trial of fluvoxamine (300 mg/day for 15 days) versus placebo in 152 COVID-19 participants.[60] Adverse events and serious adverse events were more common in the placebo arm and the single SAE in the fluvoxamine arm was dehydration and the study medication was not interrupted.[60]

**Table 5. Fluvoxamine Adverse events occurring in 10-week studies of adult OCD or depression**

\*Table shows events that occurred in  $\geq 5\%$  of adult OCD and depression study participants receiving 100-300 mg/day for 10 weeks of fluvoxamine maleate versus placebo.[59]

Adverse Reaction	Fluvoxamine, n=892 (%)	Placebo, n=778 (%)
Headache	22	20
Asthenia	14	6
Nausea	40	14
Diarrhea	11	7
Constipation	10	8
Dyspepsia	10	5
Anorexia	6	2
Vomiting	5	2
Somnolence	22	8
Insomnia	21	10
Dry Mouth	14	10
Nervousness	12	5
Dizziness	11	6
Tremor	5	1

Anxiety	5	3
---------	---	---

**Table 6. Fluvoxamine Adverse events that occurred in COVID-19 study participants receiving 300 mg/day for 15 days.**

Adverse Reaction [60]	Fluvoxamine, n=80 (%)	Placebo, n=72 (%)
Pneumonia	3.8	8.3
Shortness of breath	2.5	5.6
Headache or head pain	2.5	1.4
Gastroenteritis, nausea, or vomiting	1.3	6.9
Muscle aches	1.3	0
Bacterial infection	1.3	0
Vasovagal syncope	1.3	0
Teeth chattering	1.3	0
Dehydration	1.3	0
Low oxygen saturation or hypoxia	0	8.3
Chest pain or tightness	0	2.8
Fever	0	2.8
Acute respiratory failure	0	1.4
Serious adverse events	1.3	6.9
Other adverse events	13.8	8.3

## 16.2. Additional Appendix-Level Exclusion Criteria

1. Use of selective serotonin (or norepinephrine) reuptake inhibitors (SSRIs/SNRIs), including fluvoxamine, or monoamine oxidase inhibitors (MAOIs) within 2 weeks of consent including triptans and tryptophan. Use of fluoxetine within 45 days of consent.
2. Co-administration of tizanidine, thioridazine, alosetron, pimozide, diazepam, ramelteon, linezolid
3. Bipolar Disorder
4. Nursing mothers
5. Pregnancy\*

*\*Participants must agree to use an effective method of contraception during study drug administration and for at least 3 days after their final dose of study drug. Effective methods include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.*

### **16.2.1. Precautions**

Fluvoxamine is a potent inhibitor of CYP1A2 and 2C19 and a moderate inhibitor of CYP2C9, 2D6, and 3A4, as such, it may enhance anticoagulant effects of antiplatelets and anticoagulants as well as other medications. It is recommended that concomitant medications listed below be discussed with participants and potential effects of increased drug exposure reviewed and monitored by the participant and/or their prescribing clinician.

- Tricyclic antidepressants: monitor for side effects with amitriptyline, clomipramine, imipramine
- Antipsychotic drugs: neuroleptic malignant syndrome or similar; particularly clozapine (hypotension, seizure)
- Benzodiazepines: particularly alprazolam; recommend dose reduction
- Tramadol, buspirone, fentanyl, lithium, amphetamines, St. John's Wart, carbamazepine, quinidine, and tacrine
- Methadone: opioid intoxication
- Mexiletine: monitor for side effects
- Theophylline: recommend dose reduction and monitor for side effects
- Warfarin: monitor INR
- NSAIDs or aspirin: monitor for signs of bleeding
- Diltiazem, propranolol, metoprolol: monitor for bradycardia

**Participants should be warned about fluvoxamine inhibition of caffeine metabolism. A description is 1 cup of coffee has the effects of 4 cups while taking fluvoxamine.**

Caution should be used in participants with hepatic dysfunction due to approximately 30% increase in exposures.

### **16.3. Fluvoxamine Information**

Fluvoxamine is an FDA-approved SSRI for the treatment of OCD. Clinically it is also used for other conditions such as depression.[58] The active ingredient in fluvoxamine is fluvoxamine maleate.

#### **16.3.1. Formulation, Appearance, Packaging, and Labeling**

Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has "APO" and the other side has "F50" with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use.

**16.3.2. Drug Dispensing, Storage, and Stability**

Drug will be supplied by Apotex and distributed by Belmar Pharmacy. Study drug should be stored in controlled room temperature (20°C to 25°C); excursions are permitted to 15°C to 30°C.

**16.3.3. Dosing and Administration**


Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg BID for 10 days.

**16.3.4. Rationale for Selection of Dose**

The recommended starting dose of fluvoxamine for OCD in adults is 50 mg daily dose to be titrated up to a maximum of 300 mg/day divided into BID doses. Clinical data from the placebo-controlled, randomized trial in nonhospitalized adults with mild COVID-19 demonstrated that a 50 mg BID fluvoxamine dose was well-tolerated and effective (see [Figure 5](#)).[60] In the same study, doses of 100 mg BID in COVID-19 participants resulted in additional side effects over a 14-day period. The 300 mg daily dose is for serotonin receptor activity, whereas the postulated dose for sigma-1 receptor activity as an anti-inflammatory is lower. Therefore, the proposed dosing regimen of 50 mg BID for 10 days will use the anticipated minimal effective dose to maximize efficacy and minimize toxicity.

***Pre-Clinical Studies:***

Pre-clinical studies have indicated that the anti-inflammatory effects of fluvoxamine may support its use for treating COVID-19. Systemic inflammation as a result of infection can damage vasculature which may lead to tissue hypoperfusion and multiple organ failure.[61] Reducing systemic inflammation thereby may avoid or mitigate the aforementioned serious clinical outcomes. In murine studies, administration of fluvoxamine significantly increased survival of S1R wildtype (WT) mice and S1R knockout (KO) mice challenged with ligand lipopolysaccharide (LPS) as compared to mice that received saline ([Figure 4](#)).[61] Fluvoxamine also reduced production of inflammatory cytokines in *ex vivo* and *in vitro* murine and human cells (HEK293mTLR4/MD2/CD14, primary lung fibroblasts, and mouse bone marrow-derived macrophages) and inflammatory genes in human endothelial cells.[61, 62]




**Figure 4: Survival curve of WT and S1R KO mice**

Figure note: Mice were treated with vehicle (33% Kolliphor in saline) or STF (30 mg/kg) after administration of LPS (2 mg/kg) as indicated in (B) (n = 15 to 16 mice per group; \*\*P < 0.01, \*\*\*P < 0.001, log-rank test).<sup>[61]</sup>


#### ***Clinical Studies:***

A placebo-controlled, randomized trial in nonhospitalized adults with mild COVID-19 tested the efficacy and safety of fluvoxamine (50 mg oral one-time dose, followed by 100 mg orally twice daily for 2 days, followed by 100 mg orally three times daily through day 15) versus placebo <sup>[60]</sup>. Results of the study reported that 8.3% (6/72) of participants who received placebo experienced clinical deterioration within 15 days of randomization, as opposed to 0% (0/80) in the fluvoxamine arm (absolute difference 8.7%; 95% CI, 1.8% to 16.5%;  $P = 0.009$ ).<sup>[60]</sup> Clinical deterioration was defined as shortness of breath/pneumonia with hypoxia ([Figure 5](#)). Concomitant SSRI/SNRI dosing was not allowed per the trial protocol thus the participant's SSRI/SNRI was held for the study dosing period if reported at baseline.



**Figure 5: Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early COVID-19.**

A prospective, nonrandomized observational cohort study that evaluated fluvoxamine showed that on Day 14, 0/65 participants had persistent symptoms as opposed to 19/48 participants who did not receive fluvoxamine ( $P < 0.001$ ) [63]. Additionally, by Day 14, none of the participants who received fluvoxamine were hospitalized as compared to 6 participants who were hospitalized who did not receive the drug (see Figure 6). In this study, all participants were offered fluvoxamine and decided whether or not to take the study drug. Participants who chose to receive the study drug received 50 mg of fluvoxamine two times a day following an upfront 100 mg loading dose.[63]



**Figure 6: Summary of study results for the prospective, nonrandomized observational cohort study with fluvoxamine in participants diagnosed with COVID-19.**

**16.4. Placebo Information**

The placebo will be a fluvoxamine-matched placebo containing mannitol, magnesium stearate, hydroxyethyl cellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and purified water. The appearance and packaging will match that of the study drug (as described in Section 17.3.1). All packaging will be labeled to indicate that the product is for investigational use.

**16.4.1. Formulation, Appearance, Packaging, and Labeling**

Placebo will match the appearance of the fluvoxamine tablets: round golden 50 mg tablet that is scored on both sides - one side has “APO” and the other side has “F50” with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use.

**16.4.2. Drug Dispensing, Storage, and Stability**

Placebo will be supplied by Apotex and distributed by Belmar Pharmacy. Placebo should be stored in controlled room temperature (20°C to 25°C).

**16.4.3. Dosing and Administration**

Participants will self-administer one placebo tablet orally, twice daily for 10 days.

**16.5. Events of Special Interest**

None

## 17. Appendix C (Enrollment Closed 08FEB2022) – Fluticasone Furoate

### 17.1. Risk Assessment

The most common adverse reactions reported in  $\geq 5\%$  of adults and adolescents with lung disease include nasopharyngitis, bronchitis, upper respiratory tract infection, and headache. Long-term use of systemic and local corticosteroids may also result in the following side effects: *Candida albicans* infection, immunosuppression, hypercorticism and adrenal suppression, reduction in bone mineral density (BMD), or glaucoma and cataracts.[64]

There are insufficient data on the use of fluticasone furoate in pregnant women. There are clinical considerations with use of fluticasone furoate in pregnant women to inform drug-associated risk and benefit. In animal reproduction studies, fluticasone furoate administered by inhalation to rats and rabbits during the period of organogenesis produced no fetal structural abnormalities. The highest fluticasone furoate doses in the rat and rabbit studies were 4 times and 1 times the maximum recommended human daily inhalation dose, respectively. The estimated risk of major birth defects and miscarriage for the indicated populations is unknown. In the US general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.[64]

Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, there is an increased risk of several perinatal outcomes such as pre-eclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate.[64]

**Table 7. Fluticasone Adverse reactions that occurred in  $\geq 3\%$  of adults and adolescents with asthma in a 24-week trial.**

Adverse Reaction [64]	Fluticasone furoate, fluticasone 200 µg, n=119 (%)	Fluticasone furoate, fluticasone 100 µg, n=119 (%)
Nasopharyngitis	13	12
Headache	13	10
Bronchitis	7	12
Influenza	7	4
Upper Respiratory tract infection	6	2
Sinusitis	4	7
Oropharyngeal pain	4	3
Pharyngitis	3	6
Back pain	3	3



Dysphonia	3	2
Oral candidiasis	3	<1
Procedural pain	3	<1
Rhinitis	3	<1
Throat irritation	3	<1
Abdominal pain	3	0
Cough	3	0

### 17.2. Additional Appendix-Level Exclusion Criteria

1. Severe hypersensitivity to milk proteins
2. Currently prescribed or use within 30 days of inhaled or systemic steroids
3. Moderate to severe hepatic impairment, defined as Child-Pugh B or C
4. Nursing mothers
5. Pregnancy\*

*\*Participants must agree to use an effective method of contraception during study drug administration and for at least 3 days after their final dose of study drug. Effective methods include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.*

#### 17.2.1. Precautions

While not contraindicated, the following should be considered while taking fluticasone furoate:

- Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) should be used with caution as increased systemic corticosteroid adverse effects may occur in combination with fluticasone furoate. Generally, due to the limited study drug administration length, clinically significant interactions are unlikely.
- Paradoxical Bronchospasm may occur with an immediate increase in wheezing after dosing. Fluticasone furoate should be discontinued immediately if this occurs.

### 17.3. Fluticasone Furoate Information

Inhaled fluticasone furoate will be provided by GlaxoSmithKline. It is a synthetic trifluorinated inhaled corticosteroid (ICS) with anti-inflammatory activity. *In vitro* and *in vivo* models have shown that fluticasone furoate demonstrates anti-inflammatory actions by activating the glucocorticoid response element, inhibiting pre-inflammatory transcription factors such as NFkB, and inhibiting antigen-induced lung eosinophilia, which may contribute to its efficacy in

the approved indications. It is FDA-approved for once-daily maintenance treatment of asthma as prophylactic therapy in patients 5 years and older.[64]

### **17.3.1. Formulation, Appearance, Packaging, and Labeling**

Fluticasone furoate is an inhaled powder drug product. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder. Fluticasone furoate will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The blister strips used for this study will contain a white powder mix with a mixture of 200 µg micronized fluticasone furoate and lactose monohydrate. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.[64] All packaging will be labeled to indicate that the product is for investigational use.

### **17.3.2. Drug Dispensing, Storage, and Stability**

The study drug should be stored at room temperature (20°C to 25°C) with excursions permitted from 15°C to 30°C. It should be stored in a dry environment away from direct heat or sunlight. Unopened fluticasone furoate should be stored inside the unopened moisture-protective foil tray and only removed immediately before use. Any unused study product should be discarded 6 weeks after opening the foil tray or when the counter reads “0” (after all blisters have been used), whichever comes first. The inhaler is not reusable.[64] The study product has a shelf life of 24 months when stored at ≤ 25°C. After removal of the secondary package and the desiccant packet from the inhaler, the product may be stored up to 6 weeks at ≤ 25°C.

### **17.3.3. Dosing and Administration**

Fluticasone furoate is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.

### **17.3.4. Rationale for Selection of Dose**

Inhaled corticosteroids (ICS) have been shown to be effective in improving asthma and as a combination therapy in chronic obstructive pulmonary disease (COPD) and thus are commonly prescribed medications world-wide. Corticosteroids have been shown to have a broad range of pharmacologic activity on multiple cell types including mast cells, eosinophils, neutrophils, macrophages and lymphocytes, as well as other mediators of inflammation such as histamine, eicosanoids, and leukotrienes. In addition to the anti-inflammatory role of ICS, there is also potential for regulation of gene transcription in epithelial cells.[65-67] This regulation of gene transcription may result in inhibition of SARS-CoV-2 replication. Furthermore, in asthmatic patients, ICS may lower gene expression of ACE2 and TMPRSS2. The ACE2 receptor is expressed on epithelial cells and binds SARS-CoV-2 for entry and the serine protease TMPRSS2 primes the SARS-CoV-2 spike protein for binding. Lowering gene expression of ACE2 and TMPRSS2 may reduce binding and entry into cells therefore reducing or preventing infection.

### ***Clinical Studies:***

The PRINCIPLE (Platform Randomized trial of Interventions against COVID-19 in Older People) trial is a multicenter, open-label, multi-arm, adaptive randomized, platform trial. The trial is ongoing and released an interim analysis after the Trial Steering Committee advised the

Trial Management Group that the pre-specified superiority criterion was met on the time to recovery in the overall study population and the subgroup of participants with confirmed positive SARS-CoV-2 testing. Participants were eligible if aged  $\geq 65$  years, or  $\geq 50$  years with comorbidities and had ongoing symptoms from PCR confirmed or suspected COVID-19 with symptoms starting within the past 14 days. Participants were randomized to any open active intervention arm including inhaled budesonide and usual care. Participants were followed through an online, daily symptom diary for 28 days. Participants received usual care plus inhaled budesonide 800  $\mu\text{g}$  daily for 14 days or usual care alone. The primary outcome of the trial at the start was hospitalization or death within 28 days; however, the rate of hospitalization was lower than initially expected thus the Trial Management Group and the Trial Steering Committee recommended amending the primary outcome to include a measure of illness duration. The trial was completed with two co-primary endpoints measured within 28 days of randomization: 1) time to first reported recovery defined as the first day that a participant reported feeling recovered; and 2) hospitalization or death related to COVID-19.

The interim analysis included eligible SARS-CoV-2 positive participants who were randomized to inhaled budesonide (N=751) or usual care alone (N=1028). The mean age was 62.8 years and 83% of participants had co-morbidities. The median days from symptom onset to enrollment was 6 days. There was evidence of a benefit in time-to-first-recovery in the budesonide arm with an estimated median benefit of 3 days. The point estimate of the proportion of COVID-19 related hospitalizations or deaths was lower in the budesonide group (8.5%) versus usual care (10.3%), but this did not meet statistical significance (95% BCI -0.7 – 4.8%). There were two SAEs for hospitalization unrelated to COVID-19, both in the budesonide group.

A smaller trial of 146 nonhospitalized adults with mild COVID-19 reported that inhaled budesonide at the same dose reduced COVID-19 related emergency assessments and hospitalization.

The dose of ICS studied is PRINCIPLE is consistent with a high dose of inhaled steroid. The equivalent high dose of fluticasone furoate is 200  $\mu\text{g}/\text{day}$ . Inhaled fluticasone furoate has a greater anti-inflammatory potency per microgram than budesonide, thus fluticasone furoate is administered at a lower daily dose and used only once daily to achieve a similar high dose.

## **17.4. Placebo Information**

### **17.4.1. Formulation, Appearance, Packaging, and Labeling**

The placebo will be a fluticasone furoate-matched placebo containing lactose for inhalation in the same two tone grey inhaler that is used for the study drug. The appearance and packaging will match that of the study drug (as described in Section 18.3.1). All packaging will be labeled to indicate that the product is for investigational use.

### **17.4.2. Drug Dispensing, Storage, and Stability**

Placebo will be stored in the same conditions as study drug, room temperature (20°C to 25°C) with excursions permitted from 15°C to 30°C in a dry environment away from direct heat or sunlight. The placebo has a shelf life of up to 36 months when stored at  $\leq 30^\circ\text{C}$ .

**17.4.3. Dosing and Administration**

Participants will self-administer one blister of placebo via inhalation from the inhaler once daily for 14 days.

**17.5. Events of Special Interest**

None

**17.6. Safety Reporting for Fluticasone Furoate**

Sponsor will promptly notify GlaxoSmithKline of all SAEs, UADEs, and pregnancies (if applicable), and medical device deficiencies that have occurred for participants enrolled in this Study Drug Appendix, in accordance with the timelines and procedures specified in the Protocol/appendix. In addition, the sponsor will reasonably obtain and provide follow-up information as available, to GSK upon request.

**18. Appendix D (Enrollment Closed 22JUL2022) – Ivermectin 600****18.1. Risk Assessment**

Refer to Section 16.1.

**18.2. Additional Appendix-Level Exclusion Criteria**

Refer to Section 16.2.

**18.2.1. Precautions**

Refer to Section 16.2.1.

**18.3. Ivermectin Information**

Refer to Section 16.3.

**18.3.1. Formulation, Appearance, Packaging, and Labeling**

Refer to Section 16.3.1.

**18.3.2. Drug Dispensing, Storage, and Stability**

Refer to Section 16.3.2.

**18.3.3. Dosing and Administration**

Ivermectin should be taken on an empty stomach with water (30 minutes before a meal or 2 hours after a meal). Each participant will receive a bottle containing the number of 7-mg tablets they require based on their weight and will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight (see **Table 8**) for a daily dose of approximately 400-600 µg/kg.

**Table 8. Ivermectin 600 Dosing Schedule**

Weight (kg)	Day 1 (# of 7-mg tablets)	Day 2 (# of 7-mg tablets)	Day 3 (# of 7-mg tablets)	Day 4 (# of 7-mg tablets)	Day 5 (# of 7-mg tablets)	Day 6 (# of 7-mg tablets)	Daily Dose (µg/kg)
35-52	3	3	3	3	3	3	403-600
53-69	4	4	4	4	4	4	406-528
70-89	6	6	6	6	6	6	470-600
90-109	7	7	7	7	7	7	450-540
110-129	8	8	8	8	8	8	434-509
> 129	10	10	10	10	10	10	< 540

#### **18.3.4. Rationale for Selection of Dose**

Refer to Section [16.3.4](#).

*Additional relevant pre-clinical studies:*

Modeling studies have supported high dose and longer duration of ivermectin. One modeling study reported 600 µg/kg daily for 3 days may have clinical effect while 300 µg/kg for 3 days was unlikely to have efficacy.[68] Following this modeling study, a recently published proof-of-concept randomized controlled clinical trial in hospitalized patients showed that 600 µg/kg ivermectin for 5 days, a dose still well within the range for safety, was associated with IC<sub>50</sub> for anti-viral activity *in vitro* while lower doses (300 µg/kg) were not.[69] The anti-viral activity was identified in the subgroup of patients on ivermectin with higher mean plasma concentrations. When the ivermectin group was further divided into subgroups with 160 ng/mL as the plasma concentration cutoff, the median C<sub>max</sub> achieved was 202 ng/mL in those with plasma concentration >160 ng/mL and this group had greater reduction in viral load at day 5. These data argue for the use of higher dosing regimens in clinical trials.

The safety of higher doses of ivermectin is well understood. At least six published trials have administered ivermectin at doses above 400 µg/kg.[70] These include over 2,500 independent administrations of cumulative 800 µg/kg within one week and over 2,000 single dose administrations of 800 µg/kg. The primary side effect of higher doses, usually due to peak concentrations, is transient and mild visual disturbances not found to be structural and found to self-resolve. One such study randomized 47 patients with malaria to receive ivermectin 600 µg/kg daily for 3 days versus 300 µg/kg daily for 3 days versus placebo.[71] The 600 µg/kg group had more adverse events than the other groups. Treatment-related adverse events exhibited a dose-response relationship, with predominantly transient minor visual disturbances that were deemed non-severe.

#### **18.4. Placebo Information**

Refer to Section [16.4](#).

##### **18.4.1. Formulation, Appearance, Packaging, and Labeling**

Refer to Section [16.4.1](#).

##### **18.4.2. Drug Dispensing, Storage, and Stability**

Refer to Section [16.4.2](#).

##### **18.4.3. Dosing and Administration**

Dosing and administration will occur according to Section [19.3.3](#) in order to maintain blinding.

#### **18.5. Events of Special Interest**

- Photophobia
- Blurred vision
- Visual impairment

**19. Appendix E (Enrollment Closed 20JAN2023) – Fluvoxamine Maleate 100****19.1. Risk Assessment**

Refer to Section [17.1](#).

**19.2. Additional Appendix-Level Exclusion Criteria**

Refer to Section [17.2](#).

**19.2.1. Precautions**

Refer to Section [17.2.1](#).

**19.3. Fluvoxamine Information**

Refer to Section [17.3](#).

**19.3.1. Formulation, Appearance, Packaging, and Labeling**

Refer to Section [17.3.1](#). Fluvoxamine tablets remain 50 mg.

**19.3.2. Drug Dispensing, Storage, and Stability**

Refer to Section [17.3.2](#).

**19.3.3. Dosing and Administration**

Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg BID for one day (first two doses at 50 mg), followed by 100 mg (two 50 mg tablets) BID for 12 days (remaining 24 doses at 100 mg), for a total of 13 days (26 doses, 50 tablets) of fluvoxamine.

**19.3.4. Rationale for Selection of Dose**


Refer to Section [17.3.4](#).

*Additional relevant rationale:*

The recommended starting dose of fluvoxamine for OCD in adults is 50 mg daily to be titrated up to a maximum of 300 mg/day divided into BID doses. The 300 mg daily dose is for serotonin receptor activity, whereas the postulated dose for sigma-1 receptor activity as an anti-inflammatory is lower. The TOGETHER trial is a randomized, placebo-controlled, adaptive platform trial that demonstrated a 100 mg BID fluvoxamine dose for 10 days was well-tolerated and effective (see [Figure 7](#)) in nonhospitalized adults with mild COVID-19.[72] This is a multicenter study conducted in Brazil. Participants were > 18 years old and with symptomatic confirmed COVID-19 within 7 days of the screening date or a positive rapid antigen test done at the time of screening. Participants were required to have at least one risk factor for severe disease. Participants were randomized to active drug versus placebo, and due to the concurrent enrollment into multiple active arms, pooled placebo was used for each active arm. The primary outcome was a composite endpoint of medical admission to the hospital due to COVID-19, which was defined as more than 6 hours in an emergency care setting (acute care areas set up to respond to capacity) or referral for hospitalization, within 28 days of randomization. Key

secondary outcomes included viral clearance, time to clinical improvement, and all-cause mortality. The planned accrual, based on an assumption of 15% event rate in the placebo group, was 681 participants per arm.

The study randomized 741 participants to fluvoxamine and 756 to placebo. In the fluvoxamine group 79 (11%) participants had a primary outcome event versus 119 (16%) in the pooled placebo arm (relative risk 0.68 [95% Bayesian credible interval, 0.52-.88]). Secondary outcomes including viral clearance at day 7, hospitalization, and mortality were not different between arms. There was no significant difference in the number of treatment-emergent adverse events in the two arms. Thus, this large randomized, double-blind, controlled trial is suggestive of safety and efficacy of fluvoxamine dosed 100 mg twice daily in people with mild-to-moderate COVID-19.



**Figure 7. Probability of efficacy for the primary outcome in the ITT and mITT populations of TOGETHER**

#### 19.4. Placebo Information

Refer to Section 17.4.

##### 19.4.1. Formulation, Appearance, Packaging, and Labeling

Refer to Section 17.4.1.

##### 19.4.2. Drug Dispensing, Storage, and Stability

Refer to Section 17.4.2.

##### 19.4.3. Dosing and Administration

Participants will self-administer one placebo tablet orally BID for one day, followed by two placebo tablets orally BID (four total per day) for 12 days, for a total of 13 days of placebo tablets.



**19.5. Events of Special Interest**

For participants enrolled in the Fluvoxamine Maleate 100 appendix on protocol v7.0 or later, suicidal ideation and behavior will be assessed at Day 7 and Day 14 via the Columbia-Suicide Severity Rating Scale (C-SSRS) Screener Since Last Asked Self-Report. The C-SSRS asks a total of up to six questions and a minimum of three questions. Sites will follow local policies in response to high risk screen cases. In addition, high risk screen cases will be advised to dial 988 to access the 988 Suicide & Crisis Lifeline.

## 20. Appendix F (Enrollment Closed 23JUN2023) – Montelukast

### 20.1. Risk Assessment

The most common adverse reactions that occurred at a greater frequency in montelukast than in placebo and at an incidence rate  $\geq 5\%$  include upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, and otitis.

Post-market reports of neuropsychiatric events associated with montelukast have included agitation, hostility, anxiousness, depression, sleepwalking, suicidal thinking/behavior, and tremors.

**Table 9. Montelukast sodium adverse reactions occurring at a higher incidence than placebo, in  $\geq 1\%$  of adults and adolescents  $\geq 15$  years of age.**

Adverse Reaction	Montelukast sodium 10 mg/day, n=1955 (%)	Placebo, n=1180 (%)
Pain, abdominal	2.9	2.5
Asthenia/fatigue	1.8	1.2
Fever	1.5	0.9
Trauma	1.0	0.8
Dyspepsia	2.1	1.1
Pain, dental	1.7	1.0
Gastroenteritis, infectious	1.5	0.5
Headache	18.4	18.1
Dizziness	1.9	1.4
Influenza	4.2	3.9
Cough	2.7	2.4
Congestion, nasal	1.6	1.3
Rash	1.6	1.2
ALT Increase	2.1	2.0
AST Increase	1.6	1.2

Pyuria	1.0	0.9
--------	-----	-----

## 20.2. Additional Appendix-Level Exclusion Criteria

1. Currently participating as a study team member in support of the ACTIV-6 trial

### 20.2.1. Precautions

Participants with known aspirin sensitivity should continue to avoid aspirin and other non-steroidal anti-inflammatory agents while taking montelukast. Care should be taken with the reduction of oral corticosteroid therapy while on montelukast as systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported.

## 20.3. Study Drug Information

The primary active ingredient in montelukast tablets is montelukast sodium, which is an orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. It is indicated for prophylaxis and chronic treatment of asthma, acute prevention of exercise-induced bronchoconstriction, relief of seasonal allergic rhinitis, and relief of perennial allergic rhinitis in patients  $\geq 15$  years of age.

### 20.3.1. Formulation, Appearance, Packaging, and Labeling

Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.

### 20.3.2. Drug Dispensing, Storage, and Stability

A US commercial supply of montelukast tablets will be supplied by Accord Healthcare Inc. or Camber Pharmaceuticals and distributed by Belmar Pharmacy and Women's International Pharmacy. Montelukast tablets should be stored at 25°C with excursions permitted from 15°C to 30°C, protected from moisture and light.

### 20.3.3. Dosing and Administration

Montelukast will be self-administered orally by each participant at a dose of 10 mg (1 tablet) once daily for 14 days.

### 20.3.4. Rationale for Selection of Dose

#### *Preclinical Studies:*

Montelukast is a potent cysteinyl leukotriene receptor antagonist with anti-inflammatory effects and has been proven to significantly suppress oxidative stress and cytokine production.

Pre-clinical *in vitro* studies demonstrate montelukast's ability to act as an anti-viral agent against RNA viruses such as Zika, Influenza A, and Hepatitis C, among others.[73] A virtual screening tool, using an *in silico* molecular docking analysis, was used to simulate the binding of

montelukast to catalytically active sites within the SARS-CoV-2 main protease and RNA dependent RNA polymerase. The results indicated that the Protein-Ligand ANT System chemplp docking score of montelukast against the main protease was  $-105.71$ , and the RNA dependent RNA polymerase was  $-104.75$ . These docking scores suggest that montelukast is likely to dock to both the main protease and the RNA dependent RNA polymerase of SARS-CoV-2, therefore demonstrating the potential to inhibit the enzymatic activity of the proteins and subsequently disrupting the substrate binding site.[74]

Montelukast inhibits the signaling of NF- $\kappa$ B, such as interleukin-6,8,10, TNF-alpha, MCP-1, and other proinflammatory mediators, which may result in a corresponding reduction of proinflammatory mediators, thereby attenuating cytokine production and the cytokine storm.[75] Pulmonary and extra-pulmonary manifestations in COVID-19 are attributed to a direct effect of SARS-CoV-2 on expressed ACE2 receptors or indirectly through NF- $\kappa$ B dependent induction of a cytokine storm. Montelukast may ameliorate extra-pulmonary manifestations of COVID-19 either directly through blocking of cysteinyl leukotriene receptors in different organs or indirectly through inhibition of the NF- $\kappa$ B signaling pathway.[76]

In addition, 36.4% of patients with COVID-19 experience CNS involvement, and although the majority of these events include headache, anosmia, and dysgeusia; more serious events such as stroke, delirium, and seizures have been reported.[77] In a 6-week treatment of young (4 months) and old (20 months) rats with montelukast, a reduction of neuroinflammation was seen; elevation of hippocampal neurogenesis and improvement in learning and memory in old animals was seen. By using gene knockdown and knockout approaches, the authors demonstrated that the effect was mediated through inhibition of the GPR17 receptor.[78]

### ***Clinical studies:***

One published retrospective analysis of hospitalized patients with confirmed COVID-19 treated with or without montelukast (10 mg orally, once daily, at the discretion of the treating provider) included ninety-nine patients not previously on montelukast in the analysis (30 montelukast/62 non-montelukast). Inclusion required hospitalization for at least 3 days. Montelukast was started on day 1 of hospitalization and all patients but 1 were on hydroxychloroquine. Steroids were used by 16-23% of patients during the first 3 days of hospitalization and 33-40% of patients during the entire hospitalization. A univariate logistic regression revealed a lower risk of clinical deterioration in patients who were receiving montelukast, defined as any increase in ordinal scale from day 1 to day 3 of hospitalization, (OR, 0.23;  $P = .029$ ); however, in a multivariable logistic regression, the results in patients 60 years or older demonstrated that montelukast was not significantly associated with a reduced risk of clinical deterioration (OR, 0.28;  $P = .058$ ).[79]

A recent prospective, randomized, controlled, single-blinded, single-center study investigated standard of care treatment versus two doses of montelukast (10 mg/day or 20 mg/day) in addition to standard of care treatment in hospitalized patients with confirmed COVID-19 at the Erzurum Regional Training and Research Hospital in Turkey.[80] To be considered for enrollment, patients were required to have a PaO<sub>2</sub>/FiO<sub>2</sub> ratio above 200 at admission and to be starting on standard of care treatment (per Turkish Ministry of Health this was favipiravir for a total of 5 days). The primary outcome was a composite of progression to ARDS and/or macrophage activation syndrome (MAS). MAS was assessed at Day 5 of treatment. Clinical outcomes of disease progression were captured during hospitalization. Based on an assumption of a 20% or

greater reduction in the primary outcome, the sample size was determined to be total accrual of 180 participants enrolled (60 in each group). The two montelukast arms were combined for the clinical outcome analysis. The standard of care arm had more MAS or ARDS events (8 vs 3,  $p = 0.001$ ) and mortality (4 vs 0) than the pooled active treatment arms. There was no adverse event reporting in this manuscript, and there are numerous weaknesses to the study design.

Although the preclinical montelukast data available for SARS-CoV-2 is quite provoking, data from randomized clinical trials is lacking and the efficacy of montelukast for the treatment of COVID-19 warrants further studies. Ongoing clinical trials with montelukast propose a range of doses for testing (10 mg orally daily for 28-60 days; 60 mg orally daily for 14 days), see [Table 10](#). One completed observational study (NCT047145515) has not posted study results. The proposed dose (Section 21.3.3) of 10 mg orally daily for 14 days fills a gap for a shorter course of therapy at the FDA-approved dose for which comprehensive safety data exists.

**Table 10. Ongoing clinical trials with montelukast**

Study	Study Design	Proposed Montelukast Dose	NCT Identifier
The COvid-19 Symptom MOnTelukast Trial (COSMO)	Phase 3, randomized, blinded, placebo-controlled trial with 600 participants	10 mg daily for 60 days	NCT04389411
Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: (E-SPERANZA)	Phase 3, double-blind, randomized, placebo-controlled trial with 284 participants	20 mg daily for 28 days	NCT04695704
A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment	Phase 2, 3 arm (montelukast, montelukast plus favicovir, and favicovir), open-label, randomized trial with 380 participants	Montelukast arm dosing: 6x10 mg montelukast daily for 14 days	NCT04718285

**20.4. Placebo Information**

The placebo will match, in appearance, an FDA-approved, US commercial supply of montelukast sodium. The final packaging of the placebo will match that of the study drug (as described in Section [21.3.1](#)).

**20.4.1. Formulation, Appearance, Packaging, and Labeling**

Placebo will be tablets with the following appearance: beige, rounded square-shaped, biconvex, film-coated tablets. All packaging will be labeled to indicate that the product is for investigational use.

**20.4.2. Drug Dispensing, Storage, and Stability**

Placebo will be supplied by Almac Pharma Services and distributed by Belmar Pharmacy and Women's International Pharmacy. Placebo should be stored at controlled room temperature 25°C, excursions permitted from 15°C to 30°C.

**20.4.3. Dosing and Administration**

Participants will self-administer one placebo tablet orally daily for 14 days. Dosing and administration will occur according to Section [21.3.3](#) in order to maintain blinding.

**20.5. Events of Special Interest**

Neuropsychiatric events including agitation, hostility, anxiousness, depression, sleepwalking, suicidal thinking/behavior, and tremors.

## **21. Appendix G – Metformin Hydrochloride Immediate-Release**

### **21.1. Risk Assessment**

The most common adverse reactions (> 5%) with metformin hydrochloride include diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache. Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.

Safety concerns around metformin have centered around a risk of lactic acidosis, however the historical concern was driven by experience with other biguanides. Several large studies and Cochrane reviews have demonstrated no increased risk of lactic acidosis, and in fact fewer cases of lactic acidosis, in persons on metformin compared to other diabetes treatments.[81, 82] This includes in adults with heart failure.[83, 84] Metformin is also safe in adults with kidney disease and should not be withheld from persons with glomerular filtration rates  $>30$  mL/min/1.73m<sup>2</sup> (or lower) because of associations with improved macrovascular outcomes in persons with chronic kidney disease.[81] Guidelines recommend metformin should no longer be stopped upon hospital admission or for surgery.[85-88] Metformin's safety has been demonstrated in children and during lactation and pregnancy.[89-94]

### **21.2. Additional Appendix-Level Exclusion Criteria**

1. Chronic kidney disease including end-stage renal disease on renal replacement therapy (dialysis)
2. Chronic liver disease with ascites
3. History of metabolic acidosis and/or current use of bicarbonate supplementation
4. Current or recent use (within 14 days) of ranolazine, dolutegravir, cimetidine, pacritinib, erdafitinib, fexinidazole, patiomer, risdiplam, tafenoquine, vandetanib, zonisamide, acetazolamide, dichlorphenamide
5. Type 1 diabetes mellitus or type 2 diabetes mellitus, currently taking insulin or a sulfonylurea
6. Does not agree to less than moderate alcohol consumption\* during the Intervention Period

*\* Defined as greater than 2 drinks a day for men and 1 drink a day for women. A drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). [95]*
7. Breastfeeding or planning to breastfeed a premature infant (born at < 37 weeks of gestation) or an infant with renal impairment during the Intervention Period
8. Currently participating as a study team member in support of the ACTIV-6 trial

### **21.2.1. Precautions**

Postmarketing reports have indicated that metformin-associated lactic acidosis could result in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms of lactic acidosis include malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Risk factors of lactic acidosis include significant renal impairment, concomitant use of carbonic anhydrase inhibitors, age > 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Laboratory abnormalities from postmarketing cases included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 µg/mL. Steps to reduce the risk of and manage metformin-associated lactic acidosis in high risk groups are provided in the Full Prescribing Information. If lactic acidosis is suspected, study drug will be discontinued.

Additional precautions include Vitamin B12 Deficiency with long-term use (> 1 year), and increased risk of hypoglycemia with concomitant use with insulin and insulin secretagogues.

Alcohol can theoretically potentiate the effect of metformin on lactate metabolism, participants should be warned to avoid excessive alcohol intake. Drugs such as vandetanib may increase the accumulation of metformin; as such, concomitant use of these drugs is not allowable in the study. Excessive use of alcohol is also not allowable.

### **21.3. Study Drug Information**

Metformin hydrochloride is a biguanide and is indicated, in combination with diet and exercise, to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Metformin is an antihyperglycemic hydrochloride that is a white to off-white crystalline compound. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. This study will use the immediate release (IR) formulation of metformin.

#### **21.3.1. Formulation, Appearance, Packaging, and Labeling**

Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.

Participants will be provided with one bottle containing thirty-six 500 mg tablets. All packaging will be labeled to indicate that the product is for investigational use.

#### **21.3.2. Drug Dispensing, Storage, and Stability**

Metformin IR will be dispensed in light-resistant containers and should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15°–30°C (59°–86°F).

#### **21.3.3. Dosing and Administration**

Metformin IR tablets will be self-administered orally according to the following dosing schedule:

- 500 mg on Day 1;
- 500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and



- 500 mg in the morning and 2 x 500 mg (a total of 1000 mg) in the evening on Day 6 through Day 14.


#### 21.3.4. Rationale for Selection of Dose

Preclinical data suggests metformin has immunomodulatory activity that reduces the production of proinflammatory cytokines while stimulating the formation of neutrophil extracellular traps that may directly inhibit SARS-CoV-2.[96, 97] The hypothesis is that the primary mechanism of action for metformin against SARS-CoV-2 relies on metformin's availability in the plasma. The systemic exposure of IR metformin is higher than for extended-release (XR) metformin. Anti-viral medications are also considered more effective when started early in the course of infection, and IR metformin is faster to reach systemic levels above 500 ng/mL.

While the preclinical data shown in [Figure 8](#) and [Figure 9](#) use a dose of 2000 mg per day of IR, 2000 mg per day is also the dose at which the risk of side effects increases significantly ([Figure 9](#)). Rapidly increasing the dose to 2000 mg per day within 2 weeks appeared to increase the risk of side effects. The proposed dose of 1500 mg daily balances the need to achieve a consistent dose and an effective dose without causing side effects. A dose titration is typically important when starting metformin, to avoid side effects and study drug discontinuation.

#### *Preclinical Studies:*


Preclinical data supports the use of the IR formulation to achieve systemic exposure. One study with samples from 19 evaluable patients receiving a single dose of metformin demonstrated higher plasma metformin levels in those who received IR as opposed to delayed-release [DR] ([Figure 8](#)). A randomized, phase 2, parallel-group, multicenter, placebo-controlled study of double-blind placebo or 4 doses of metformin DR and single-blind metformin IR (2000 mg) similarly showed higher systemic metformin plasma levels following dosing of an IR formulation as opposed to DR ([Figure 9](#)).



**Figure 8. Mean (SD) plasma metformin concentrations by treatment and time point after a single daily dose of metformin.**

Figure Note: Treatments were administered at  $t = 0$  h (8:00 p.m.) and at  $t = 12$  h (8:00 a.m.) except for metformin (Met) XR, which was administered as a single dose at  $t = 0$  (black arrows).

Meals were administered at  $t = -0.42, 2.08, 11.5, 18.08,$  and  $24.08$  hours relative to the first dose (dotted vertical lines).[98]



**Figure 9. Metformin systemic (plasma) exposure**

Figure Note: (A) observed at trough (median) and (B) steady state AUC<sub>0-24h</sub> (geometric mean [95% CI]) estimated from trough and post-dose sampling. Efficacy presented as (C) Hemoglobin A1C (HbA1c) change at Week 16 (Least squares mean + standard error) and (D) Average concentration Week 4–16 change in fasting glucose from baseline (Least Squares mean + standard error). Data are from the mITT population (n = 542), with the exception of modeled steady-stated metformin AUC<sub>0-24h</sub> (ITT population; n = 571). \* p<0.05 vs. Placebo. The ITT population consisted of participants randomized on Day 1 who received at least one dose of randomized study medication. The mITT population consisted of ITT participants with at least one post-baseline value for HbA1c that was collected no more than 1 week after discontinuing study medication and prior to taking a new anti-diabetic concomitant medication that could reasonably be expected to influence subsequent glycemic data.[99]

### Clinical Studies:

Metformin IR is more widely available and less expensive than XR or DR metformin. Metformin IR is over the counter in some countries, like Brazil and Spain, but XR and DR formulations are not.

While several studies have investigated metformin in the SARS-CoV-2 population, the IR formulation appears to result in improved outcomes as opposed to other formulations. The TOGETHER Trial performed in Brazil compared metformin DR (750 mg twice daily for 10 days) to placebo in a total of 418 participants with confirmed SARS-CoV-2 infection, including symptoms within 7 days of Screening and one additional high-risk criterion. The results showed no difference in the primary outcome of hospitalization or > 6 hours of retention in a COVID-19 emergency setting between metformin DR and placebo. Additionally, no clinical improvement (according to the World Health Organization clinical worsening scale) was identified at 28 days.[72] The TOGETHER Trial did not have a dose titration, and starting at 1,500 mg per day would be expected to cause side effects in a large portion of participants. Thus, the per-protocol results might be more informative from the TOGETHER Trial, and the per-protocol results do suggest a benefit for metformin. In the per-protocol analysis, 4.76% (8 of 168) in the metformin group versus 7.82% (14 of 179) of controls were hospitalized.

Another trial performed in Mexico compared metformin IR (620 mg twice daily for 14 days) to placebo in a total of 20 participants with type 2 diabetes mellitus who presented with severe acute respiratory syndrome secondary to SARS-CoV-2 infection. The results showed a significant reduction in the viral load of those who received metformin IR (93.2%) as opposed to those on placebo (78.3%) and lower supplemental oxygen intake on days 2, 5, and 7 in those who received metformin IR (5.9 points) versus those on placebo (10.6 points).[97]

One trial of metformin IR for outpatient treatment of COVID-19 has been completed in the US, COVID-OUT. Metformin IR prevented over 40% of emergency department visits, hospitalizations, and death due to COVID-19 (OR 0.58, 95% CI, 0.35 to 0.94) by Day 14. By Day 28, those in the metformin IR group were also less likely to be hospitalized, 1.34% (8/596) versus 3.16% (19/601) of those receiving placebo. Treatment with metformin IR during acute COVID-19 infection prevented over 40% of Long COVID cases, with 6.3% of participants in the metformin IR group and 10.6% in the placebo group receiving a diagnosis of Long COVID from a medical provider.[100]

## **21.4. Placebo Information**

### **21.4.1. Formulation, Appearance, Packaging, and Labeling**

Placebo tablets will be provided by The University of Iowa Pharmaceuticals and Almac Pharma. One bottle of 36 placebo tablets will be provided to participants who are randomized to receive placebo. All packaging will match that of the active drug supply and will be labeled to indicate that the product is for investigational use.

### **21.4.2. Drug Dispensing, Storage, and Stability**

Placebo will be stored in the same conditions as study drug, room temperature (20°C to 25°C) with excursions permitted from 15°C to 30°C in a light-resistant container.

### **21.4.3. Dosing and Administration**

Participants will self-administer placebo according to the following schedule:

- One (1) placebo tablet on Day 1;

- One (1) placebo tablet in the morning and 1 placebo tablet in the evening on Day 2 through Day 5; and
- One (1) placebo tablet in the morning and 2 placebo tablets in the evening on Day 6 through Day 14.

### **21.5. Events of Special Interest**

- Lactic acidosis will be reported as an ESI if the event is reported during a hospitalization
- Occurrence of hypoglycemia will be recorded on Day 14 by asking the participant to report any healthcare provider documented occurrence of low blood sugar

### **21.6. Statistical Considerations for Acute Disease**

The most significant effect of metformin described in COVID-OUT was for a combination outcome of mortality, hospitalization and emergency department visits. Therefore, healthcare utilization will be the variable used for PPOS for this appendix.

### **21.7. Statistical Considerations for Post-acute Disease**

Recent data suggest that metformin may reduce the risk of PASC, or Long COVID. ACTIV-6 provides an opportunity to validate this finding in a robust way given the collection of patient reported outcomes through 180 days. At 180 days, participants complete the PASC symptom questionnaire in addition to general symptom reporting, clinical event reporting, and QOL. These data can be used to assess the influence of metformin.

The SAP provides details on the analysis of the PASCD endpoint, which is specific to the metformin appendix. As noted in the sample size considerations below, up to 3000 participants may be needed to determine whether metformin reduces the risk of PASCD. Given the increase in sample size, analysis of the primary endpoint will proceed only after all participants have been enrolled to answer the independent research question.

#### **21.7.1. Primary Hypothesis**

The primary hypothesis for post-acute disease (Appendix G only) is that participants who receive metformin will have lower risk of PASCD at day 180 compared to those who receive placebo. The day 180 endpoint (PASCD) is applicable for participants who were consented to the study after protocol v7.0 was implemented.

#### **21.7.2. Sample Size Considerations**

From 1 January 2022 to 31 December 2022, ACTIV-6 enrolled 4498 patients, of whom 3751 patients responded to day 90 surveys (83.4% response rate). Of those responding, 262 reported persistent symptoms at 90 days. As it currently stands, ACTIV-6 is powered at about 80% to detect a reduction in risk from 7% to 3.5% (a 50% relative risk reduction; required sample size for 80% power is 1272). Under more conservative assumptions of a 40% relative risk reduction from 6% to 3.6% among responders only, 2488 participants would be needed. If the rate of symptom persistence is lower, say 5%, slightly larger sample sizes would be required. A halving of risk from 5% to 2.5% would require 1812 participants for 80% power, and a 40% relative risk reduction to 3% would require 3012 participants. We will therefore increase accrual for the main analysis to ~3000.

Given the independence of the research questions related to treatment of acute COVID with 28-day outcomes and to the prevention of PASCD with outcomes assessed at 180 days, the SAP will not adjust for multiplicity due to assessing both questions. A futility analysis on the PASCD endpoint will be conducted when 600 participants in Appendix G have passed day 180 under the assumption of accrual to  $n=3000$ . The SAP will address the influence of interim analyses on Type 1 error as appropriate.

**21.7.3. Interim Analysis**

- i) Secondary Objective IA ( $n=600$  passing Day 90): A futility analysis on the PASC endpoint will be conducted when 600 participants have passed day 90 under the assumption of accrual to  $n=3000$ .